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Idiopathic inflammatory myopathies (IIM), a group of rare chronic inflammatory disorders, 
are characterized by a broad spectrum of clinical manifestations with high morbidity and 
mortality. The pathogenesis of IIM is largely unknown but accumulating evidence suggests 
that autoantibodies promote the initiation and perpetuation of the disease. The aims of this 
thesis were 1) to increase the understanding of the role of anti-Jo1 antibodies and the histidyl-
t-RNA synthetase (HisRS) autoantigen in the pathogenesis of the anti-synthetase syndrome 
(ASS), a distinct subgroup of IIM; 2) to study the incidence and the prevalence of a life-
threatening comorbidity of IIM, the arterial and venous thrombosis, and to assess the 
contribution of traditional risk factors, disease characteristics and biomarkers to its 
occurrence.  
Paper I: A sensitive electro-chemiluminescence immunoassay (ECLIA) was developed to 
detect HisRs in serum. For the first time, HisRS was found to circulate extracellularly in the 
serum of healthy individuals and, with higher concentrations, in the serum of anti-Jo1- 
patients. Serum levels of HisRS were, instead, undetectable in anti-Jo1+ patients and 
correlated negatively with anti-HisRS autoantibody levels in serum. A human muscle cell 
culture was set up showing that primary human myoblasts could release HisRS in the culture 
medium with increasing amount during differentiation into myotubes and upon stimulation 
with insulin growth factor 1. The tolerance to endogenous HisRS was efficiently disrupted in 
different strains of wild-type mice by immunizing mice with murine full-length (FL) HisRS 
and WHEP. No obvious muscle or lung inflammation was observed in immunized mice 
compared to control mice. However, upon external induction of tissue-specific damage, the 
degree of immune engagement with consequent muscle damage and lung injury was 
significantly exacerbated in immunized mice compared to controls. The administration of 
HisRS in mice previously lung or muscle-challenged resulted in a significant reduction of the 
inflammation in both lungs and muscle tissue. Moreover, in vitro, HisRS inhibited the 
activation of T cells isolated from fresh blood of human healthy donors.  
Paper II and III: Total IgG were isolated from anti-Jo1+ and anti-Jo1- patients as well as 
from healthy controls (HC) and glycans appended to the Fc region of the IgG were explored 
and compared between the three groups. The Fc-glycan profile of the anti-Jo1 IgG isolated 
from anti-Jo1+ patients was also investigated. Total IgG and specifically anti-Jo1 IgG from 
IIM/ASS patients displayed a pro-inflammatory Fc-glycan profile (i.e. agalactosylation) 
which was overrepresented in patients with interstitial lung disease (ILD). Anti-Jo1 IgG 
specifically presented lower abundance of bisected and afucosylated forms and Fc-glycan 
characteristics correlated positively with proteins involved in inflammatory processes. 
IgG and IgA were isolated from serum and matching bronchoalveolar lavage fluid (BALF), 
collected at time of diagnosis and longitudinally, of anti-Jo1+ and anti-Jo1- patients as well 
as from HC to determine the reactivity levels against the FL-HisRS protein and its different 
constructs and splice variants. Reactivity levels of IgG and IgA isolated from BALF and 
serum of anti-Jo1+ patients were found to be high already at the time of diagnosis and in some 
cases even before diagnosis, generally decreasing thereafter. Highest reactivity was 
registered against the HisRS-FL and the HisRS splice variants. Moreover, IgG against 
HisRS-FL displayed high affinity already at the time of diagnosis. Patients with high 
reactivity levels towards HisRS-FL were more likely to have ILD and arthritis, but less likely 
to have skin rash. Noteworthy, IgG anti-WHEP reactivity in BALF correlated with poor 
pulmonary function.  
In Paper IV, the incidence of venous thromboembolic events (VTE) was assessed in patients 
with IIM in comparison to the general population and patient categories at high risk and the 
timing of risk in relation to the diagnosis of IIM were identified. In Paper V, the prevalence 
of arterial and venous TE was retrospectively investigated in a large cohort of IIM patients 
and possible traditional and/or disease-related risk factors and biomarkers linked to arterial 
and venous TE in patients with IIM were explored.  
The incidence rate of VTE was significantly higher in IIM patients than in the general 
population, especially during the first year after diagnosis, and remained that high even after 
adjusting for education level, comorbidities, cancer, treatment at baseline and competing risk 
of death. Among IIM patients, the risk of VTE was even more elevated in those with a history 
of cancer, in patients with DM, and in those with age !72 years. In the retrospectively 
assessed cohort of IIM patients, one out of 5 patients had presented with an arterial and/or 
venous TE at the same time of or after the diagnosis of IIM. Even though a higher frequency 
of male gender and essential hypertension were observed in IIM patients with reported TE 
and of malignancy in those with history of exclusively venous TE, only older age was an 
independent risk factor for TE occurrence, while autoantibodies and clinical variables did not 
contribute. Interestingly, lower levels of e-selectin correlated with higher odds of getting TE 
in IIM patients.  
 
In conclusion, the discovery of HisRS extracellularly in both healthy individuals and IIM 
patients supports the hypothesis that HisRS exerts other physiological functions beyond the 
known intracellular protein synthesis. The inhibition of T cell activation by HisRS and the 
impact of HisRS in reducing the degree of inflammation in mice previously immunized 
against HisRS and with previously induced tissue damage suggest a possible 
immunosuppressive activity of this protein. This could open the path for a potential new 
therapeutically approach in anti-Jo1 positive patients. The inflammatory Fc-glycan profile as 
well as the high reactivity and affinity levels in serum and BALF of anti-Jo1 antibodies 
(conversely undetectable serum HisRS levels) already at the time of and even before 
diagnosis represent new evidence supporting the role of anti-Jo1 antibodies in the 
pathogenesis of IIM/ASS. The high incidence and prevalence of arterial and venous 
thrombotic events in patients with IIM, especially close to diagnosis and in those older, male 
patients with essential hypertension and history of malignancy, should indicate that a proper 
screening and preventive measures need to be recommended in this patient population. E-
selectin levels could be used as biomarkers to identify IIM patients at higher risk of 
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In 1901, the German scientist and physician Paul Ehrlich speculated on the possibility that the 
immune system might misdirect its attack by producing toxic antibodies for self-tissues (1). He 
was indeed reluctant to the idea that this phenomenon, he named “horror autotoxicus”, could 
actually lead to illness (2). In fact, he hypothesized the presence of protecting mechanisms to 
avoid that the organism ultimately harms itself (1). After more than one century, we are able to 
acknowledge his brilliant intuition by describing the sophisticated ability of the immune system 
to selectively recognize the foreign substances or non-self-antigens while not reacting to native 
antigens. The so-called breaking of immunological self-tolerance and the consequent initiation 
of an autoimmune response is considered to be the crucial event leading to the development of 
an autoimmune disease. Despite major advances in understanding which genetic and 
environmental factors or infectious pathogens may contribute to the exposure of autoantigens 
to the immune system and to the start of clonal multiplication of autoreactive T cells and to 
autoantibody production, the etiology and the pathogenesis of the majority of known 
autoimmune diseases are still poorly understood (3).  
Autoimmune diseases represent a unique medical challenge because of the high complexity and 
heterogenicity of clinical phenotypes with frequent multiple organ involvement, high morbidity 
with big impact on quality of life and current lack of tailored target therapy with curing purpose. 
So far, more than 80 autoimmune diseases have been described, affecting 5% of the world 
population and being a major burden for the economic and health care system (4, 5). Therefore, 
a better understanding of the pathogenic mechanisms that govern these conditions is highly 
relevant to identify preventive and therapeutic approaches. 
This PhD thesis focuses on a group of chronic inflammatory systemic disorders, the idiopathic 
inflammatory myopathies (IIM), where accumulating evidence suggests that an aberrant 
activation of the immune system plays a central role in the initiation and perpetuation of the 
systemic inflammation. 
1( Immunological tolerance  
Immunological tolerance refers to a state of unresponsiveness of the adaptive immune system 
toward a given specific antigen. The absence of immune reaction towards native or self-antigens 
is defined as immunological self-tolerance. Numerous regulatory pathways are needed to 
prevent immune responses when immature lymphocytes encounter native antigens in the 
primary lymphoid organs (central tolerance) or when mature lymphocytes encounter antigens 
in peripheral or secondary lymphoid tissues under particular conditions (peripheral tolerance) 
(3, 6-8).  
1.1( Mechanisms of central tolerance 
Central tolerance for immature B-lymphocytes and T-lymphocytes occurs in the bone marrow 
and in the thymus, respectively. In the bone marrow, immature B-lymphocytes that encounter 
a native antigen undergo apoptotic cell death or they change specificity of the surface-bound 
immunoglobulins which constitute the B cell receptor, a phenomenon known as “receptor 
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editing”. The recognition of any antigen by T cells through the specific T cell receptor (TCR) 
occurs only if the antigen peptide is presented in the niche formed by class I or class II alleles 
of the major histocompatibility complex (MHC) on the surface of any nucleated cell type for 
MHC-I and on professional antigen presenting cells (APC) for MHC-II. In the thymus, 
immature T cells with TCR showing no affinity for the MHC-peptide complex are neglected 
and die (positive selection of T lymphocytes with sufficient affinity of the TCR for the MHC-
peptide complex). The pool of positive selected T cells contains lymphocytes recognizing both 
exogenous and self-antigens. T-lymphocytes with high affinity TCR for self-peptides in the 
context of MHC undergo apoptotic cell death (negative selection) (3, 6-8).  
1.2( Mechanisms of peripheral tolerance 
Autoreactive mature B and T cells that escaped central tolerance migrate to secondary lymphoid 
organs. Autoreactive B cells lacking proper activation signals may enter a state of anergy. This 
happens, for instance, when B cells encounter an antigen in absence of T helper lymphocytes. 
APC, in particular dendritic cells (DC), are involved in the regulation of peripheral T cell 
response. Downregulation of co-stimulatory molecules on APC (CD80 and CD86) blocks the 
activation of autoreactive T cells which become anergic or are deleted. 
Regulatory T cells or T-regs, a specific T cell subgroup, are capable to suppress immune 
responses through secretion of cytokines such as interleukin-10 (IL-10), transforming growth 
factor (TGF)-!, IL-35 and by altering/limiting DC function (3, 6-8). 
2( Definition of autoimmunity and autoimmune disease 
Abolition of immunological self-tolerance, due to failure of regulatory checkpoint mechanisms, 
induces the selection of autoreactive B and T cell clones (9). This does not automatically result 
in an autoimmune disease. At a certain level, autoimmunity is a physiological event and a pool 
of autoreactive lymphocytes in the immune cell repertoire is actually maintained since it has 
been shown to be crucial for immune system development and for prevention of pathogenic 
autoimmunity (10).  
Therefore, an autoimmune disease develops when, in individuals with genetic susceptibility, 
upon exposure to environmental, infectious or internal triggers, an aberrant response of the 
adaptive immune system to a self-antigen leads ultimately to tissue injury (9). Widely accepted 
proofs of pathogenic autoimmunity are 1) the identification of autoreactive T cells and/or 
autoantibodies in the affected organ or tissue; 2) the induction of the disease after transferring 
autoreactive T cells and/or autoantibodies in healthy individuals or animals or after immunizing 
animal models with the autoantigen; 3) the improvement of the clinical manifestations after 
eliminating or suppressing the autoimmune response (5, 11). 
2.1( Genetic susceptibility 
 
A low number of autoimmune diseases are caused by mutations in single genes and are 
therefore indicated as monogenic autoimmune diseases (12, 13). Examples are the autoimmune 
poly-endocrinopathy syndrome type 1 induced by a mutation in the autoimmune regulator gene 
(AIRE) which affects the negative selection in the thymus and thus self-antigen presentation 
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(12, 13) and the X-linked immunodysregulation poly-endocrinopathy enteropathy (IPEX) 
syndrome caused by a mutation within the gene FOXP3 involved in the generation of regulatory 
T cells (14). In the majority of patients, genetic factors, such as rare (<1%) or common (>1%) 
single nucleotide polymorphisms (SNPs), copy-number variants and epigenetic modifications, 
are claimed to confer higher susceptibility for development of autoimmune diseases (15). 
Genome-wide association studies have shown that genetic variants of human leukocyte antigen 
(HLA) genes within the MHC locus on the chromosome 6 and of genes outside the MHC locus 
but with crucial roles in pathways of B-cell and T-cell activation or innate receptor signaling 
(e.g. IRF5, STAT 4, PTPN22, TNFSF4) are strongly associated with several autoimmune 
diseases (13, 15). Some risk alleles may predispose for more than one autoimmune disease. For 
instance, the haplotype MHC class II molecule HLADR3 and, in particular, HLA-DRB1*0301 
associates with Type I diabetes (16), idiopathic inflammatory myopathies (IIM) (17) and 
systemic lupus erythematosus (SLE) (18).  The haplotype DR4 and its HLADRB1 subtypes 
(shared epitope) correlate, instead, with Rheumatoid Arthritis (RA) (19). 
2.2( Environmental triggers 
Specific genetic components do not account alone for risk of being affected by autoimmune 
diseases. In fact, the concordance rate of autoimmune diseases in monozygotic twins is between 
12 and 65% (13). Environmental factors, proposed as triggers in genetic predisposed 
individuals, include infectious agents, chemicals and pharmaceutical agents, nutrition, the 
microbiota, hormones, smoking, ultraviolet light, collagen/silicone implants, heavy metals, 
vaccines (13, 15).  
2.3( Autoantigens 
An aberrant autoimmune response, with autoreactive T cells and autoantibodies as main actors, 
is often directed to: 
•( tissue-restricted autoantigens (e.g. beta cells of the pancreatic islets in Type I Diabetes 
(20) or thyroglobulin/thyroid peroxidase in Hashimoto thyroiditis (21)); 
•(  ubiquitously expressed autoantigens, albeit resulting in distinct clinical phenotypes 
(e.g. Sm-ribonucleoproteins and double-strand DNA in SLE (22-25) or anti-
topoisomerase-1 in diffuse scleroderma with interstitial lung disease (26)).  
The association between the immune reactivity to a certain autoantigen and a particular clinical 
phenotype is not affected by the frequency of autoantibody reactivity in a specific patient 
population (27). For instance, antibodies to citrullinated proteins are specifically found in 70-
90% of patients with RA (28) as well as anti-alanyl-tRNA synthetase antibodies are detected in 
less than 5% of patients with unique anti-synthetase syndrome (29).  
With some exceptions, as for example in RA with autoantibodies against the Fc portion of IgG 
in serum (rheumatoid factor) (30), many autoantigens targeted in systemic autoimmune 
diseases are localized intracellularly, in nuclei, cytoplasm, bound to organelles and cell-
membrane and are part of multimolecular machines with important role in DNA replication, 
DNA repair, RNA processing and splicing, gene expression, protein translation (27).   
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The events listed below may explain why an intracellular autoantigen becomes suddenly visible 
to the immune system and elicits autoantibody production (Figure 1): 
•( Post-translational modifications (PTMs), i.e. alteration of the amino-acid sequence of 
the protein due to e.g. phosphorylation, deamination, glycosylation, ubiquitination, 
citrullination, occur physiologically after protein synthesis and impacts protein folding, 
protein functions and interaction with other proteins (31). Under pro-inflammatory 
circumstances and cell death, protein structure modifications may reveal new or cryptic 
epitopes otherwise not presented to T cells ensuing an autoimmune process (32, 33). 
Antibodies targeting citrullinated peptides in RA represent an example of strong 
association between PTMs and an autoimmune disease (34). 
•( During cell death induced by granule-mediated cytotoxic T lymphocytes (CTL), 
autoantigens may undergo proteolytic modifications. Unique autoantigen protein 
fragments are generated, for instance, by Granzyme B (GrB) cleavage, a serine protease 
contained in CTL granules (35). Immune epitopes have been found close to cleavage 
GrB sites, suggesting that the GrB cleavage may mediate novel antigen presentation 
(36). Higher expression of cleaved forms of autoantigens has been observed in target 
tissues of autoimmune diseases (36), e.g. the GrB-cleaved histidyl-t-RNA synthetase 
(HisRs/Jo-1) autoantigen is almost exclusively found in the lungs of patients with anti-
synthetase syndrome (37) or the GrB cleaved form of the nucleolar autoantigen 
nucleophosmin in differentiated smooth cells of patients with systemic sclerosis and 
pulmonary hypertension (38).  
•( In case of impaired clearance of apoptotic cells and defective degradation of neutrophil 
extracellular traps, NETs during NETosis, intracellular components such as DNA, 
histones, ribonucleoproteins are enriched at the surface of the cells in apoptotic bodies 
and become immunogenic, triggering autoantibody production. This is known to 
contribute, for instance, to the pathogenesis of SLE (39, 40). 
•( the immune system can cross-react to self-molecules which present a significant 
homology with the structure of a microbial agent, a phenomenon known as molecular 



















response to treatment (49). In anti-neutrophilic cytoplasmic antibodies (ANCA)-associated 
vasculitis (AAV), ANCA titers significantly decrease or disappear during remission and, 
conversely, increase in case of active disease or before a recurrent event (50). In RA, even 
though the presence of anti-citrullinated peptides antibodies (ACPA) is associated with more 
aggressive disease and development of bone erosions, studies on the relationship between the 
variation of ACPA titers and disease progression or response to therapy showed variable results 
(51-53).   
Beyond the role as serological biomarkers, autoantibodies can directly induce systemic 
inflammation and tissue injury and are, in this case, indicated as pathogenic. 
To understand how pathogenic autoantibodies are generated and behave, it is important to start 
from the following general concepts: 
•(  Antibody structure: two heavy (H) chains and two light (L) chains held together by 
disulfide bonds. Both heavy and lights chains contain constant (C) and variable (V) 
domains. The four constant domains at the C-terminal of the two heavy chains constitute 
the fragment crystallizable region (Fc) stem of the immunoglobulin which mediate 
effector functions through binding to Fc receptors (FcR) on other cells of the immune 
system and via complement activation. The Fc part is also linked to diverse glycans 
which determine the glycosylation pattern of the antibody (54). The variable arms 
(fragment antigen-binding, Fab), composed of the two light chains and the N-terminal 




Figure 2. Antibody structure. a) the antibody is basically composed of a light chain with a variable and constant 
region and a heavy chain with a variable region, a hinge and three constant region domains, each with different 
functions. The glycan is attached to Asn297 in the CH2 domain. b) the antibody glycan with possible combination 
of sugars. Reprinted by permission from Springer Nature, Nikolay Nikolow et. al., An FDA perspective on the 
assessment of proposed biosimilar therapeutic proteins in rheumatology, Nature Review Rheumatology 13, (123-
127), 2017 
•( Antibody diversity: the constant regions of the heavy and light chains are encoded by 






IgE, IgD) and sub-class of the antibody (immunoglobulin isotype class switch 
recombination) as well as the different effector Fc properties. The high variability of 
the Fab regions is due to point mutations inserted into the genes encoding the variable 
sequences, a process called somatic hypermutation. This allows the binding with a 
vast number of potential antigens (55). 
•( Polyclonal versus monoclonal antibodies: polyclonal antibodies are antibodies showing 
reactivity to different epitopes of one antigen and produced by plasma cells which 
originate from multiple B lymphocytes clones. Monoclonal antibodies derive from one 
single B lymphocyte clone and recognize only one epitope of the antigen (57).  
•( Antibody specificity: the ability to recognize a specific epitope in presence of other 
epitopes. The higher the specificity, the lower is the cross-reactivity of the antibody with 
several epitopes of different antigens (57). 
•( Antibody affinity and avidity: the strength of the bond between the antibody and the 
antigen or, in other words, the capacity of the antibody to dissociate from the antigen, 
measured with the dissociation constant K, determines the antibody affinity. The higher 
the K, the lower the affinity and vice versa. Antibodies repeatedly exposed to the same 
antigen acquire greater affinity for the antigen (affinity maturation). Antibodies can 
bind antigens with multiple binding sites as well as antigens can bind more than one 
antibody (antibody and antigen valency). The overall strength of a multivalent 
interaction between the antibody and the antigen is measured by avidity (57, 58).   
 
Natural autoantibodies, circulating in healthy individuals at a concentration of 1-2 mg/ml in the 
blood, are commonly polyclonal IgM with low affinity and minimal somatic hypermutations. 
They provide the first defense against pathogens and are involved in regulation of B cell 
development and B cell responses and in protection against cancer (59).  
Pathogenic autoantibodies, instead, are somatically mutated and affinity maturated polyclonal 
and monoclonal immunoglobulins, belonging to any class type, but preferentially IgG and IgA 
(59). They may present with altered glycosylation pattern (60, 61). Their pathogenetic action 
can be exploited directly, by stimulating or suppressing the antigen function (e.g. Grave’s 
disease mediated by antibodies against thyroid stimulating hormone receptor (62)), or indirectly 
through two major pathways: 
•( Formation of immune complexes which precipitate in targeted tissues and activate the 
complement system leading to direct cell lysis and recruitment of leukocytes to remove 
the antigen and enhance inflammation. 
•( Binding to FcR-carrying effector cells, such as monocytes, macrophages, dendritic 
cells, neutrophils, mast cells, platelets and natural killer cells, which determine 
activation of tyrosine kinases, stimulation of phagocytosis, degranulation and release of 
cytokines and inflammatory mediators, and antibody-dependent cellular cytotoxicity 
(63, 64).  
Indirect pathogenic effects are claimed, for instance, for ANCA and ACPA in AAV and RA, 
respectively (63). 
At the experimental level, proofs of autoantibody pathogenicity can be obtained in vitro by 
demonstrating autoantibody-related cellular damage or immune activation, or in vivo, by 
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observing the occurrence of an autoimmune disease after passive transfer of autoantibodies in 
animal models (65, 66). At clinical level, the presence of autoantibodies in serum years before 
the onset of the disease (67, 68) (e.g. ACPA in RA (69)), with characteristics as epitope 
spreading, affinity maturation, glycosylation changes, isotype switching, as well as the 
effectiveness of B-cell target therapies are considered indirect evidences of pathogenicity (64). 
2.5( Autoreactive T cell driving autoantibody production and tissue injury 
Processes like B cell maturation, B cell clonal expansion, differentiation of B cells into plasma 
cells, somatic hypermutation, and immunoglobulin class switching take place in germinal 
centers (GC) of secondary lymphoid organs. These processes are regulated by the follicular T 
helper cells (Th), a distinct CD4+ T helper cell subset, which originate from naïve CD4+ T cells 
through antigen stimulation and interactions with APC (70). In autoimmune diseases, targeted 
tissues, such as the synovia in RA and the kidney in SLE, often present with ectopic GC where 
cross-talk between T and B cells is crucial for production of high affinity autoantibodies (15, 
70). Autoreactive follicular Th cells selectively activate those B cells reactive to the same 
antigen recognized by T cells. Thus, antigens bound to autoantibodies include the peptide 
recognized by autoreactive CD4+ T cells. It follows that the specific B cell autoimmune 
response is generally antigen-driven and T cell dependent (64, 70).  
Autoreactive CD4+ T cells together with APC are also important to induce the recruitment of 
autoreactive CD8+ T cells responsible for direct killing of target cells. The activation of 
autoreactive CD8+ T cells and their transformation into effector cytotoxic T cells require the 
binding with the complex MHC class I-autoantigen at the surface of the target cell or of the 
APC. Once activated, CD8+ T cells kill target cells through degranulation of cytolytic enzymes 
like perforin and granzyme B, induction of apoptosis through Fas-Fas-ligand and release of 
cytokines such as tumor necrosis factor-# (TNF-#) and interferon-" (IFN-") (13, 71, 72). 
2.6( Active role of target tissue in autoimmunity 
Target tissues of pathological autoimmune responses are not simply passive bystanders. 
Physiologically, pro-inflammatory and anti-inflammatory pathways within the tissue are finely 
regulated and balanced. This allows to fight infections or tumors by avoiding excessive tissue 
damage. In individuals genetically susceptible to autoimmune diseases, tissue intrinsic 
mechanisms that control or inhibit inflammation can be defective. In presence of pro-
inflammatory cytokines, target cells are self-capable of releasing chemokines which induce the 
migration of activated T and B lymphocytes to the tissue. Once in the tissue, the activated 
lymphocytes interact directly with target cells which start to up-regulate MHC-class I and co-
stimulatory molecules. In this way, chronic inflammation is established and autoimmune tissue 
destruction is promoted (15, 73).  
 
 9 
3( Idiopathic inflammatory myopathies 
 
The term idiopathic inflammatory myopathies (IIM), in short myositis, refers to a group of 
rare chronic inflammatory disorders. Even though the word myositis literally means muscle 
inflammation, the burden of inflammation is indeed systemic, affecting in most cases not 
only skeletal muscle but even the skin, lungs, heart, joints and the gastrointestinal tract. 
Typical muscular symptoms are muscle weakness and impaired muscle endurance which lead 
to problems in walking, climbing stairs or lifting objects above the head. Within extra-
muscular symptoms, skin rash, dyspnea and dry cough due to interstitial lung disease (ILD), 
arthritis, Raynaud’s phenomenon, mechanic’s hands, and fever are widely recognized (74). 
The heterogenicity of clinical manifestations and their broad range of severity explain why 
the diagnosis is often a challenge for the clinicians who needs to collaborate with experts in 
different disciplines such as the rheumatologist, neurologist, pulmonologist, cardiologist, 
pathologist, and physiotherapist. 
By combining different sets of diagnostic and classification criteria based on serological tests 
including autoantibodies, clinical, histological features and imaging, the following subgroups 
can be distinguished: polymyositis (PM), dermatomyositis (DM), juvenile dermatomyositis 
(JDM), clinically amyopathic dermatomyositis (CADM), immune-mediated necrotizing 
myopathy (IMNM), cancer-associated myositis (CAM), overlap myositis (OM), anti-
synthetase syndrome (ASS), and sporadic inclusion body myositis (sIBM) (75).  
3.1( Epidemiology 
Idiopathic inflammatory myopathies belong to the group of rare diseases (76). Accurate 
epidemiological data is difficult to provide because of large variation of ethnical, 
geographical and diagnostic/classification criteria applied in different studies. According to 
a systematic literature review of 16 surveys published in 2015, the overall IIM incidence was 
estimated at 7.98 cases/million/year (95% CI 7.38, 8.66) between 1951 and 2010 (76). After 
analyzing the results of 10 surveys, overall IIM prevalence was estimated at 14 cases/100 
000 inhabitants (95% CI 12.84, 15.46) between 1982 and 2010 (76). Exactly the same 
prevalence of IIM was found in Sweden, as described by a nation-wide population study 
published by our research group in 2017 (77). The Swedish IIM incidence, instead, was 
higher with reported 11 new cases per million people per year with age peak at 50-79 years 
(77). At IIM subgroup level, OM, DM and IMNM account for almost 90% of myositis cases 
(78). DM was the most common diagnosis among 3067 patients in the Euromyositis registry 
(79) and a higher frequency of DM cases has been observed closer to the equator (80, 81). 
The female gender is generally more affected with a female: male ratio of 2:1 (76) with the 
exception of sIBM where the ratio is inverted (76). Few population-based studies have 
investigated the incidence and prevalence of sIBM, reporting 1.2-4.9 incident cases per 
million per years (76) and a prevalence ranging from 14.9 per million in Australia in 2007 
(82) up to 35 per million in Norway in 2014 (83). Two peaks of age at onset, the first before 
the age of 20 and the second between 44-55 years for IIM as a whole and 60-65 years for 




3.2( Diagnostic and classification criteria 
3.2.1( Bohan and Peter criteria 
 
In 1975, Bohan and Peter (84, 85) proposed the diagnostic and classification criteria with a 
sensitivity of 94-96% and a specificity of 29-55% (86). They have been widely used for more 
than 40 years. The criteria included 5 variables (Table 1) and were able for the first time to 
differentiate DM from PM, however not between PM and sIBM. 
3.2.2( Griggs criteria 
 
The more frequently used diagnostic and classification criteria for sIBM were postulated by 
Griggs et al. in 1995 (Table 2) (87). According to the evaluation of diagnostic criteria for 
sIBM made by Lloyd et al. (88) the sensitivity of Griggs criteria is 11-29%, while the 
specificity is 100%. 
Table 2 
Griggs criteria for diagnosis of sIBM (87) 
A. Clinical features 
1. Duration > 6 months  
2. Age of onset > 30 years  
3. Weakness Proximal and distal of arms and legs and must exhibit at least one of: a. Finger flexor weakness; b. 
Wrist flexor > extensor weakness; c. Quadriceps weakness " Grade 4 MRC  
B. Laboratory features 
1. Creatine kinase < 129 UI/L normal  
2. Muscle biopsy 
a. Inflammatory myopathy (with partial invasion)  
b. Rimmed vacuoles  
c. Either 
i. Intracellular amyloid deposits, or  
ii. 15- to 18-nm tubulofilaments by EM  
Diagnostic criteria: (i) Definite IBM = all muscle biopsy features. None of the clinical/laboratory features are 
mandatory and (ii) Possible IBM = partial invasion with- out other pathological features + characteristic clinical 
and other laboratory features.  
Legend: IBM, inclusion body myositis; EM, electron microscopy; MRC, medical research council’s scale 
3.2.3( EULAR/ACR criteria 
 
The EULAR/ACR (European League against Rheumatism/American College of 
Table 1 
Bohan and Peter’s diagnostic criteria for PM and DM (84, 85) 
First, rule out all other forms of myopathies  
1. Symmetrical weakness, usually progressive, of the limb-girdle muscles with or without dysphagia and 
respiratory muscle weakness  
2.  Muscle biopsy evidence of myositis  
Necrosis of type I and type II muscle fibers; phagocytosis, degeneration, and regeneration of myofibers with 
variation in myofiber size; endomysial, perimysial, perivascular, or interstitial mononuclear cells.  
3.  Elevation of serum levels of muscle-associated enzymes (CK, LDH, transaminases, aldolase)  
4. EMG triad of myopathya. Short, small, low-amplitude polyphasic motor unit potentials b. Fibrillation 
potentials, even at restc. Bizarre, high-frequency repetitive discharges  
5. Characteristics rashes of dermatomyositis 
 
Definite PM: all first four elements, probable PM: 3 of first 4, possible PM: 2 of first 4.  
Definite DM: rash plus 3 others, probable DM: rash plus 2 others, possible DM: rash plus 1 other  




Rheumatology) criteria (89), published in 2017, are data driven and developed by a multi-
disciplinary team, aimed to identify IIM patients with a broad spectrum of phenotypes and to 
capture those with minimal or absent muscle involvement. Sixteen variables are weighted 
differently on the basis of their ability to contribute to the diagnosis. Compared to several of 
previous classification criteria a myositis-specific autoantibody, anti-Jo-1 is included. The 
sum of each score provides the probability of having IIM. A probability of 55% had the best 
sensitivity of 87-93% and specificity of 82-88%. The criteria can be applied even when 
muscle biopsy is not available if typical skin rash is present. The included items and 
corresponding scores are listed in Table 3. 
Table 3 
EULAR/ACR criteria for diagnosis of IIM (85) 







Age of onset of first symptom assumed to be related to disease ! 18 and < 40 years 1.3 1.5 
Age of onset of first symptom assumed to be related to disease ! 40 years 2.1 2.2 
Muscle weakness   
Objective symmetric weakness, usually progressive, of the proximal upper extremities 0.7 0.7 
Objective symmetric weakness, usually progressive, of the proximal lower extremities 0.8 0.5 
Neck flexors are relatively weaker than neck extensors 1.9 1.6 
In the legs, proximal muscles are relatively weaker than distal muscles 0.9 1.2 
Skin manifestation   
Heliotrope rash 3.1 3.2 
Gottron’s papules 2.1 2.7 
Gottron’s sign 3.3 3.7 
Other clinical manifestation   
Dysphagia or esophageal dysmotility 0.7 0.6 
Laboratory measurements   
Anti-Jo1 autoantibody present 3.9 3.8 
Elevated serum levels of CK or LDH or ASAT/AST/SGOT* or ALAT/ALT/SGPT* 1.3 1.4 
Muscle biopsy features - presence of   
Endomysial infiltration of mononuclear cells surrounding but not invading myofibers  1.7 
Perimysial and/or perivascular infiltration of mononuclear cells  1.2 
Perifascicular atrophy  1.9 
Rimmed vacuoles  3.1 
Anti-Jo1, anti-histidyl-tRNA synthetase; CK creatine kinase; LDK, lactate, dehydrogenase; ASAT/AST/SGOT, 
aspartate aminotransferase; ALAL/ALT/SGPT, alanine aminotransferase 
 
3.3( Myositis specific and associated autoantibodies 
 
Myositis specific autoantibodies (MSAs) represent specific diagnostic markers for IIM and 
are commonly mutually exclusive (90, 91). Exact overall prevalence of MSAs is difficult to 
determine due to the availability of different tools for detection and lack of standardized 
guidelines (92). However, based on large cohort studies including children and adults with 
IIM, MSAs may be detected in approximately 60-70% of patients (93-95). MSAs target 
intracellular self-antigens with role in DNA transcription, chromatin remodeling, epigenetic 
modifications, protein synthesis or translocation, muscle cell metabolism and differentiation, 
innate immune response (96, 97). MSAs are associated with specific phenotypes, disease 
course and response to treatment (96-100). Name of known MSAs, target autoantigens, 
association to clinical subgroup and frequency in IIM are summarized in Table 4A. 
Myositis associated autoantibodies (MAAs) occur in more than 50% of patients with IIM 
(95, 101), but they are not disease-specific, also being found in other connective tissue 
diseases. Common MAAs are anti-Ro/SSA, anti-Ku, anti-PM/Scl and anti-U1 
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ribonucleoprotein antibodies (U1RNP) (96) (Table 4B).  
 
Table 4 
A.( Myositis specific autoantibodies (74, 96, 101-104) 
Autoantibody Autoantigen Associated clinical subgroup 
Frequency in adult 
IIM (%) 
anti-aaRS Aminoacyl-t-RNA synthetases ASS 30 
anti-Jo1 Histidyl-t-RNA synthetase ASS 15-25 
anti-PL7 Threonyl-t-RNA synthetase ASS 3-5 
anti-PL12 Alanyl-t-RNA synthetase ASS 3-5 
anti-OJ Isoleucyl-t-RNA synthetase ASS <5 
anti-EJ Glycyl-t-RNA synthetase ASS <5 
anti-KS Asparaginyl-t-RNA synthetase ASS <2 
anti-Zo Phenylanalanyl-t-RNA synthetase ASS <2 
anti-Ha (YRS) Tyrosyl-t-RNA synthetase ASS <2 
anti-Mi-2 Nuclear DNA helicase DM, JDM 2-45 (4-10 in JDM) 
anti-TIF1" Trascriptional intermediaryfactor 1 " DM, CAM, JDM 5-20 (20-30 in JDM) 
anti NXP2 Nuclear matrix protein 2 DM, CAM, JDM 10-15 (20-25 in JDM) 
anti-MDA5 Melanoma differentiation associated gene 5 DM, CADM, JDM 15-30 
anti-SAE SUMO activating enzyme Severe DM 2-8 (<2 in JDM) 
anti-SRP Signal recognition particle INMN 5 (<2 in JDM) 
anti-HMGCR 3-hydroxy-3-methylglutaryl- CoA reductase INMN 5-8 (1 in JDM) 
anti NT5C1a Cytosolic 5’-nucleotidase 1A sIBM 30-76 in sIBM 
anti-FHL1 Four-and-a-half LIM protein Severe myopathy 25 
 
B.( Myositis associate autoantibodies (96, 104) 
Autoantibody Autoantigen Associated clinical subgroup 
Frequency in adult 
IIM (%) 
anti-U1RNP  U1 small nuclear RNP OM 10 (5 in JDM) 
anti-Ro52 Ro52/TRIM21 ASS, OM 20-30 (6 in JDM) 
anti-Ku Ku complex OM < 1 
anti-Pm-Scl Nucleolar protein complex OM 8-10 (5 in JDM) 
 
3.4( Serological, histopathological and clinical profile of the myositis subsets 
3.4.1( Polymyositis (PM) 
 
Polymyositis commonly affects adults in their middle-age presenting with proximal and 
symmetrical muscle weakness, creatine kinase (CK) elevation, myopathic pattern on 
electromyography (EMG), and muscle edema on magnetic resonance imaging (MRI) in 
absence of skin manifestations. The muscle biopsy typically reveals spread MHC-I 
upregulation and cytotoxic CD8+ T cells invading non-necrotic muscle fibers, even though 
these findings are not specific for PM and may be observed in sIBM, but less frequently in 
DM and ASS (Figure 4a-b-c). PM is rarely an isolated pathological condition but it is 
frequently part of the overlap myositis or ASS subgroups. Moreover, PM could be 
misdiagnosed with sIBM or muscular dystrophies due to similar clinical presentation in the 
early phase.  
None of the known MSAs are exclusively associated to PM (74, 75, 102). 
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3.4.2( Dermatomyositis (DM, JDM, CADM) 
 
Dermatomyositis occurs in both children (juvenile DM, JDM) and adults with peak of 
incidence between 50-60 years old, more frequently in women and with higher prevalence in 
geographical areas close to the equator (75, 81).  
A violaceous, periorbital and edematous rash known as heliotrope rash (Figure 3d), 
erythematous scaly bumps over joints, often the MCP joints -so called Gottron’s papules 
(Figure 3f), erythematous flat rash on elbows and knees (Gottron’s sign, Figure 3a-b-c), on 
anterior of the chest (V-sign) or on shoulders and back (Shawl sign), or over the hips (Holster 
sign) represent pathognomonic skin features. Active skin lesions may resolve leaving areas 
of hyperpigmentation, telangiectasias and atrophy (poikiloderma, Figure 3e). Periungual 
erythema, Raynaud’s phenomenon and pruritus are quite common among patients with DM. 
Skin biopsies reveal an interface dermatitis characterized by lichenoid inflammation of the 
dermal-epidermal junction, vacuolar changes in the epidermidis and perivascular 
inflammation, although not specific for DM (Figure 3g).  
Symmetrical muscle weakness can precede or accompany the skin rash or may be absent as 
in the CADM (74, 75, 102). CK may raise up to 50 times the upper limit of normal range or 
may be normal. Usually, a myopathic pattern is observed at EMG. MRI shows muscle edema 
in the muscle fascicles or around them as result of fascial involvement. The muscle edema 
reflects the presence of fluid due to inflammatory cell infiltrates composed of plasmocytoid 
dendritic cells, T (CD4+) and B lymphocytes, and macrophages which typically infiltrate the 
perimysium or surround medium-size blood vessels and capillaries. The latter are also site of 
membrane attack complex (MAC) deposition which is, together with the perifascicular 
atrophy, specific histopathological findings of DM. As in other subgroups, MHC-I is often 
up-regulated on the sarcolemma of muscle fibers (Figure 4c, 4e-f).  
DM patients with circulating antibodies (Ab) towards Mi-2 nuclear antigen often present with 
classical DM skin features and mild muscle inflammation with a favorable disease course 
and good response to treatment. Anti-TIF-1" and anti-NXP2 Ab are common in JDM and, in 
case of anti-NXP2, skin lesions are often complicated by calcinosis. Only in adults, anti-
TIF1" and NXP2 Ab are strongly associated with malignancy within 3 years from DM 
diagnosis (103). Severe and aggressive skin involvement with development of ulcers is 
expected in presence of Ab recognizing SAE or MDA5. Anti-MDA5 Ab may occur in DM 
patients with mild or absent muscle inflammation (CADM) and rapidly progressive ILD, 
















particularly in those with more severe clinical picture and higher mortality rate. Indeed, anti-
NT5C1a Ab are not specific for sIBM, occurring even in 5–10% of patients with PM, 15–
20% of patients with DM, 10% of patients with SLE and 12% with Sjögren’s syndrome (SS). 
sIBM overlaps with SS in approximately 15% of cases, displaying in circulation anti-Ro and 
anti-La antibodies (74, 75, 102, 106, 108).  
3.4.4( Immune-mediated necrotizing myopathy (IMNM) 
 
Immune-mediated necrotizing myopathy is a distinct subgroup characterized, clinically, by 
severe and rapidly progressive proximal muscle weakness of the arms and legs, very high 
CK elevation up to 20-50 folds the upper normal limit, myopathic EMG changes, muscle 
edema at MRI and, histologically, by necrosis of muscle fibers, minimal lymphocytic 
infiltration, macrophage infiltrates, MHC-I upregulation and MAC deposition on non-
necrotic fibers (Figure 4d). In children, although vary rare, the clinical picture could be 
extremely difficult to differentiate from dystrophies. Extra-muscular manifestations are rare. 
Two MSAs are associated with IMNM, anti-SRP and anti-HMGCR antibodies. Anti-SRP 
positive patients are usually younger, weaker, with higher degree of muscle necrosis, atrophy 
and fatty replacement and higher likelihood to present with extra-muscular features such as 
ILD and cardiomyopathy compared to those with circulating anti-HMGCR Ab. Up to 60% 
of anti-HMGCR positive patients have been exposed to prior intake of statins, HMGCR 
inhibitors and lipid-lowering medications, which do not associate with presence of anti-SRP 
antibodies. Autoantibody-negative patients with IMNM have higher risk of malignancy 
compared to those with anti-SRP and anti-HMGCR antibodies. Prognosis of IMNM is worse 
than in the other IIM subgroups due to high rate of persistent muscle weakness despite 
treatment (102, 106, 109-111). 
3.4.5( Overlap myositis (OM) 
 
Overlap myositis (OM) is a clinical entity where myositis accompanies clinical features of 
other connective tissue diseases (CTD), such as SLE, systemic sclerosis or Sjögren’s 
syndrome. Overlap of myositis and systemic sclerosis, also recognized as a distinct entity 
called scleromyositis (112), accounts for the majority of cases. Some authors classify a 
patient as affected by OM if criteria for both IIM and CTD are fulfilled; others require only 
the presence of myositis plus one of the overlap manifestations even without meeting CTD 
criteria. MAAs, particularly anti-Ro, anti-U1RNP, anti-PmScl, anti-Ku, are frequently found 
in OM, alone or together with autoantibodies specifically found in the associated CTD. 
Muscle involvement is generally mild and muscle enzymes are slightly elevated. Arthritis, 
esophageal dysmotility, Raynaud’s phenomenon and ILD are the most common extra-
muscular manifestations. There are few studies looking at the histopathological findings in 
OM, showing a biopsy pattern closer to the one observed in DM than in other subgroups  
(113-115). 
3.4.6( Cancer-associated myositis (CAM) 
The diagnosis of cancer-associated myositis can be made when a patient presents with cancer 
within three years from the diagnosis of myositis (116). Malignancy may occur before, 
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concurrent with or after the myositis diagnosis. The risk of developing cancer is highest 
during the first year after diagnosis (117). Although cancer has been observed in all IIM 
subgroups (116), DM is the most common. Data on type of cancer vary depending on the 
population included in the study. According to a pooled analysis from Sweden, Denmark and 
Norway published in 2001 (118), adenocarcinomas of the lungs, ovaries, and breasts were 
frequently found in DM patients, while hematological malignancies such as non-Hodgkin 
lymphoma in PM patients. Ovarian cancer is the most frequent malignancy in CAM 
diagnosed in European and North American cohorts, but not in the Asiatic cohorts where 
nasopharyngeal and lung cancers are the most frequent (116). Among clinical and laboratory 
parameters, older age, male gender, skin ulcerations and skin necrosis, elevated CK and 
inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), HLA-A28 type 
have been associated with higher risk of malignancy in IIM patients (116). On the contrary, 
ILD, anti-Jo1 antibodies, and arthritis/arthralgia have been found to protect from cancer in 
some IIM cohorts (116). In CAM, the clinical manifestations of the IIM subgroup are 
considered to be a paraneoplastic phenomenon as supported by several observations of their 
improvement or worsening in case of cancer remission or recurrence, respectively (119-121). 
Significant higher prevalence of malignancy has been observed in IIM patients testing 
positive for anti-TIF1" or anti-NXP2 autoantibodies. A meta-analysis of six studies including 
312 patients with IIM showed that presence of anti-TIF1" antibodies has a 70% sensitivity 
and 89% specificity for diagnosing cancer-associated myositis, with positive predictive value 
of 58% and negative of 93% (122, 123). Moreover, a study conducted by our research group 
demonstrated that serum levels of anti-TIF1" antibodies may be detected before the onset of 
cancer and may disappear in case of cancer remission after successful treatment (124). These 
findings support the important role of anti-TIF1" antibodies in identifying IIM patients at 
high risk for malignancy who should carefully be screened and monitored. In three 
independent studies, anti-NXP2 antibodies have been associated with cancer in male patients 
above the age of 54 years with DM, mostly within one year from DM diagnosis (125-128). 








EJ, OJ, KS, Ha and Zo, Table 4A) is mandatory to make the diagnosis of ASS, while the 
clinical spectrum is often heterogeneous, whereby isolated or combined features are possible. 
Anti-Jo-1 antibodies are found in 15-30% of patients with IIM and in up to 90% of those with 
ILD. Autoantibodies targeting other aaRS are less common, each with prevalence below 5% 
(93).  
Anti Jo-1 positive patients usually present with myositis, arthritis or ILD, while anti-PL7 and 
anti-PL12 are strongly associated with isolated severe ILD. Clinically, muscle involvement 
may be consistent with both PM and DM, while histologically, perifascicular atrophy similar 
to the pattern in DM seems to be predominant. In addition, electron microscopy-based 
nuclear actin aggregation has been seen only in ASS muscle biopsies but not in others IIM. 
Severity range of ILD is broad, going from asymptomatic cases to acute distress respiratory 
syndrome. Within ILD patterns, non-specific interstitial pneumonia (NSIP) is the most 
frequent, followed by usual interstitial pneumonia (UIP) and cryptogenic organizing 
pneumonia (COP). Cumulative survival seems to be higher in aaRS positive patients with 
ILD compared to those with idiopathic pulmonary fibrosis (IPF). Arthritis usually occurs at 
the onset of ASS, being rheumatoid arthritis-like especially in ASS patients testing positive 
for ACPA antibodies. Mechanic’s hands, described as erythematous and fissured 
hyperkeratosis of the palmar or lateral edges of the fingers, highly correlate with ASS 
diagnosis, although also reported in others overlap myositis, especially in presence of anti 
Pm-Scl antibodies. Raynaud’s phenomenon is not a specific feature of ASS and it has more 
frequently been observed in patients with anti-PL12 and anti-PL7 than in patients with others 
aaRS. Relapsing-remitting fever is one of the symptoms in nearly 20% of ASS patients (79, 
102, 106, 132-135).  
3.5( Diagnostic workup and assessment of disease activity and damage 
 
An extensive diagnostic work-up is needed to characterize which tissues/organs are involved 
by the inflammatory process and to choose the most appropriate treatment. 
After collection of a precise medical history including information on smoking, history of 
neuro-muscular and/or connective diseases in the family, exposure to myopathic drugs and 
toxins, following investigations are usually performed: 
•( Evaluation of muscle strength by manual muscle test 8 (MMT8) and of muscle 
endurance by functional index test (FI-2 or FI-3) (136); 
•( Serum levels of muscle enzymes (CK, lactate dehydrogenase (LDH), myoglobin, 
aspartate-amino transferase (AST) and alanine aminotransferase (ALT)); 
•( Analysis of MSAs and MAAs; 
•( Electromyography to look for a typical myopatic pattern with small amplitude, brief, 
polyfasic action potentials;  
•( MRI of the muscles to look for fascial and/or muscle oedema, muscle atrophy and fatty 
replacement of the muscles; 
•( Muscle biopsy; 
•( Inspection of the skin and possible skin biopsy; 
•( Capillaromicroscopy in case of severe Raynaud’s phenomenon; 
•( Peripheral joint status, ultrasound and x-Ray of the affected joints; 
•( Evaluation of lung involvement by high-resolution computer tomography (HRCT) and 
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pulmonary function tests; 
•( Evaluation of cardiac involvement by serum levels of NT pro-BNP (N-terminal of 
prohormone of brain natriuretic peptide), electrocardiography, ecocardiography and 
MRI of the heart; 
•( Evaluation of gastro-intestinal tract by esophagus x-ray with barium or 
videofluoroscopy in case of swallowing difficulties; 
•( Screening for malignancy. 
The evaluation of disease activity is based on the following disease activity core set measures 
identified by the International Myositis Assessment & Clinical Studies group (IMACS) 
(137): 
1.( Physician’s global disease activity measured by visual analogue scale (VAS); 
2.( Patient’s global disease activity measured by VAS; 
3.( Manual muscle test (MMT)-8 to evaluate the muscle strength; 
4.( Health assessment questionnaire of activities of daily living (HAQ); 
5.( Serum levels of muscle enzymes (at least two of the following: CK, LDH, AST, ALT); 
6.( Extra muscular activity score: evaluation of constitutional, cutaneous, gastrointestinal, 
articular, cardiac, and pulmonary activity by using Myositis Disease Activity 
Assessment Tool (MDAAT) 
Improvement is defined as 3 of 6 core set measures improved $ 20%, with no more than 2 
(not including MMT-8) worsening by $ 25% (137). The Total Improvement Score (range 0-
100) is the sum of the improvement scores assigned to the 6 IMACS core set measures. Total 
improvement scores $20, $40, $60 represent minimal, moderate and major improvement, 
respectively, as defined by ACR/EULAR response criteria (138).  
Evaluation of damage is based on the IMACS Myositis Damage index scoring (MDI) (139) 
which assesses the persistent changes in anatomy, physiology, pathology or function present 
for at least six months in eleven organ systems (muscle, skeletal, cutaneous, gastrointestinal, 
pulmonary, cardiovascular, peripheral vascular, endocrine, ocular, infection, malignancy).  
3.6( Treatment of IIM 
 
Despite the progress in identifying and sub-classifying IIM patients with different 
characteristics, the treatment approach is still far away to be tailored to the single patient and 
treatment recommendation is mainly based on open studies and case reports rather than 
randomized-controlled trials. High dose glucocorticoids represent the first choice to reduce 
muscle inflammation. Moreover, extra muscular manifestations, especially skin rash, arthritis 
and ILD, in general also respond well to steroids. To straighten steroid efficacy or as steroid-
sparing agents, conventional disease modifying drugs (azathioprine, methotrexate, 
calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide), biologic and 
immunomodulatory agents (rituximab, abatacept, anakinra, tocilizumab, JAK-inhibitors, 
intravenous immunoglobulins) are frequently added in the early phase of the disease and their 
choice is often guided by the main organ involvement. Combination of multiple 
immunosuppressive drugs and biologic/immunomodulatory agents or step-up approach are 
preferred in case of severe and rapidly progressive weakness, dysphagia or ILD. As a 
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complementary treatment, physical exercise programs should be strongly recommended at 
any phase to improve muscle strength and prevent disability. Among IIM subsets, sIBM is 
known to be resistant to treatment with immunosuppressive agents with a relentless course 
leading to progressive loss of function in daily activities (140-144). Several trials 
investigating new pathways possibly involved in the pathogenesis of IIM are now ongoing 
(www.myositis.org; https://clinicaltrials.gov). 
3.7( Morbidity and mortality in IIM 
 
Despite the advances in treatment strategies, IIM are still characterized by high morbidity 
and mortality impact (145).  
Morbidity is related to muscle symptoms, extra-muscular manifestations, especially those 
associated with lung, heart and esophageal involvement, infectious complications, steroid 
and immunosuppressive drug toxicity, and malignancies (145). According to short- and long-
term outcome studies, remission rate varies from 20 to 70%, indicating that a consistent group 
of patients will instead experience relapsing-remitting or chronic symptoms (145-148). 
Studies assessing functional disability status and quality of life showed persistent mild to 
moderate disability and decreased quality of life in more than 50% of patients with IIM (147, 
149, 150).  
Even though the 5-year survival rate has improved with the availability of glucocorticoids 
and immunosuppressive drugs, IIM patients have a significant higher risk to die early 
compared to the general population. Main causes of death are cardiovascular disease, 
respiratory failure due to ILD or infections, and cancer. The ranking order of causes of death 
differs between studies. The most important predictors of mortality are older age, male 
gender, non-Caucasian ethnicity, smoking, cardiovascular diseases, ILD, cancer, skin ulcers, 
dysphagia and longer duration of symptoms (145, 151).  
The cardiovascular comorbidities in IIM patients will be discussed in detail in Chapter 5. 
3.8( Disease mechanisms in IIM 
 
Interactions between specific genetic and environmental factors are thought to be the triggers 
of both immune and non-immune mediated mechanisms involved in the pathogenesis of IIM. 
Activation of different pathways in genetically predisposed individuals upon exposure to 
certain environmental components could explain the occurrence of specific symptom 
constellations which characterize the various IIM subsets (Figure 5) (152, 153). 
3.8.1( Genetic risk factors 
Genome-wide association studies (GWAS) have shown that the strongest disease association 
lies within the MHC region on chromosome 6 (154, 155). HLA-DRB1*03:01 strongly 
correlates with PM and sIBM, while HLA-B*08:01 with DM. HLA-DRB1*01:01 and HLA-
DRB1*13:01 have been specifically found in patients with sIBM. Moreover, different HLA 
alleles and certain amino-acids positions in the HLA region may differentiate between adults 
and children, among ethnic groups and associate with distinct MSAs. For instance, in anti-
HMGCR positive patients with IMNM, HLA-DRB1*11:01 and HLA-DRB1*07:01 associate 
with adult and juvenile patients, respectively (153, 156-158). Non-HLA loci, including 
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PTPN22, TRAF6, BLK, STAT4, PLCL1, CCR5, have been linked to IIM. The association 
with the mentioned genes supports the implication of both innate and adaptive immune 
responses in the pathogenesis of IIM (153). 
3.8.2( Environmental risk factors 
Genetic variants identified from GWAS and, in particular, Immunochip studies cannot 
explain alone the heterogenicity of the IIM clinical picture (159). Several epidemiological 
studies, case series, and animal models have investigated the possible association between 
infectious agents, drugs or environmental components and IIM. Examples of microorganisms 
suspected to be inducers of IIM are the human immunodeficiency virus (HIV), the human T-
lymphotropic virus-1 (HTLV-1), Hepatitis B, Toxoplasma, Borrelia, and group A 
Streptococcus (153). Infections of the respiratory tract have been associated with increased 
likelihood of presenting with IIM (160). Beyond the known correlation between treatment 
with statins and occurrence of IMNM, even drugs as D-penicillamine, colchicine, 
chloroquine, interferons, anti-TNF-alpha agents have been claimed to act as potential triggers 
of IIM (153). Among environmental factors, probably the most relevant observation is that 
smokers who are carriers of HLA-DRB1*03:01 have increased probability to develop anti-
Jo1 antibodies (161). In addition, UV-radiation has been reported to correlate with DM and 
anti-Mi-2 antibodies (162, 163). 
3.8.3( Immune mediated mechanisms 
The muscle microenvironments in IIM is enriched with myeloid and plasmocytoid dendritic 
cells, macrophages, T and B cells supporting the role of both innate and adaptive immune 
system in the pathogenesis of IIM (152, 153).  
CD8+ T effector T cells can be seen invading non-necrotic muscle fibers of PM-sIBM patients 
by releasing perforin and granzyme-B (152, 153, 164, 165). CD4+ T cells mainly constitute 
the perivascular inflammatory infiltrate in the muscle of DM patients (166). Affected muscles 
may also present infiltrates of pro-inflammatory T cells, CD8+ or CD4+ lacking the co-
stimulatory molecule CD28 (CD8+ or CD4+ CD28null), with cytotoxic properties and 
apoptosis resistant, which have been correlated with poor response to treatment (167-170). 
Studies on JDM have also suggested possible impairment of the Tregs subset (171, 172). The 
presence of B cells, plasma cells, immunoglobulins transcripts in the muscle of IIM patients 
as well as the strong association between MSAs and specific IIM subsets strongly suggest 
that the humoral component of the immune system is as well implicated (152, 153). Direct 
proofs for the pathogenicity of the MSAs are still lacking but supporting evidence is growing 
for anti-Jo1, anti-HMGCR, anti-Mi-2 and anti-c1A antibodies (173-175). The state of the art 
on the possible role of anti-Jo1 antibodies in the pathogenesis of IIM/ASS will be discussed 
in detail in chapter 4.  
Muscle cells and immune-infiltrating cells highly express innate immune receptors as Toll-
like receptors which, in turn, activate NF-KB signaling, cytokine and chemokine secretion. 
This leads to further recruitment of immune cells which will interact with antigen presenting 
dendritic cells. The latter are the major source of type I interferons (IFNs), key cytokines in 
IIM and in particular in DM. Overexpression of the genes induced by type I IFN has been 
observed in muscle, skin, blood of DM patients with levels of type I IFNs correlating with 
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disease activity (176-179). IFN# and IFN! were shown to have toxic effects on muscle tissue 
and to induce up-regulation of MHC-I on muscle cells, increasing the susceptibility of the 
muscle fibers to the attack from the immune system (180, 181). MAC deposition in the wall 
of intermediate-size vessels of muscle and skin of DM patients reveals that the complement 
cascade is also activated leading to endothelial cell swelling, vacuolization, expression of 
vascular adhesion molecules and recruitment of T cells to the site of inflammation in 
perimysial and endomysial spaces (152).  
So far, the muscle has been the major source of information on immune-mediated 
mechanisms in IIM. However, there is growing evidence supporting the lung as site of 
possible immune activation in IIM/ASS. This will be explored in more detail in chapter 4.  
3.8.4( Non-immune mediated mechanisms 
In some patients with IIM, the severity of the clinical symptoms does not correlate with the 
degree of inflammation in muscle biopsy or there is a progressive worsening despite active 
immunosuppressive treatment. These observations motivated to investigate whether non-
immune mediated mechanisms play a role in the pathogenesis of IIM. The best studied non-
immune pathways are 1) hypoxia; 2) the endoplasmic reticulum stress (ER) with consequent 
accumulation of unfolded proteins, release of free radicals, up-regulation of TNF-related 
apoptosis-inducing ligand (TRAIL), expression of heat-shock proteins HSP70 and HSP90 
and the alarmin high mobility group box protein 1 (HMGB1); 3) impairment of autophagy; 
4) mitochondrial dysfunction (152, 153). Major details are beyond the purpose of this 
summary and will not be discussed.  
 
Figure 5 
Figure 5.  
Immune and non-
immune mechanisms 
involved in the 
pathogenesis of IIM.  
Genetic and environmental 
factors influence the 
adaptive and innate 
immune response, and this 
leads to the activation of 
several cellular 
components (neutrophils, 
NK cells, macrophages, 
mast cells, dendritic cells, 
B cells, and T cells such as 
CD8+, CD4+, Treg, Th17, 
CD28
null
) involved in the 
inflammatory response. 
However, other 
mechanisms are involved 
in this complex scenario,  
including non-immune mechanisms such as autophagy, endoplasmic reticulum stress, and hypoxia. 
Reprinted after permission from Springer Nature, Ceribelli A. et al., The Immune Response and the 





4.2( Autoimmunity against HisRS autoantigen in the pathogenesis of IIM/ASS 
In vitro experiments demonstrated that HisRS can be secreted from cells (195), but in vivo 
secretion and presence of HisRS in extracellular compartments have not been reported so far. 
How and where HisRS becomes the target autoantigen of a specific immune response in 
IIM/ASS is still unknown. Notably, the pathogenic role of antibodies against HisRS (anti-
Jo1 Ab) is suggested by clinical and epidemiological observations: 1) prominent association 
between anti-Jo1 Ab and distinct clinical entity such as ASS (135); 2) anti-Jo1 Ab titers 
correlate with disease activity and may be found before the disease onset (199, 200); 3) 
smoking appears to be associated with an increased risk of possession of anti-Jo1 Ab in HLA-
DRB1*03-positive IIM cases (161); 4) anti-Jo1 Ab are mutually exclusive, generally not 
occurring with other myositis specific autoantibodies (201).  
The HisRS antigen is expressed at low levels in all cells including healthy muscle fibers and 
at high levels in inflamed muscles and regenerating fibers. This suggests that it is unlikely 
that the immune response towards HisRS starts in unperturbed muscles. HisRS is also 
expressed by bronchial epithelial lung cells from healthy individuals and with a higher 
expression in the bronchial epithelial cells compared to other cells (37, 202). Proteins may 
become immunogenic when cleaved in aberrant ways (203) and Levine et al. showed that 
HisRS can be cleaved by granzyme B (GrB) in the lung, potentially revealing neo-epitopes. 
HisRS seems to be more susceptible to the GrB cleavage in the lung than in other tissues, 
including muscle and the cleaved conformation of HisRS is recognized by anti-Jo1 Ab (37). 
The main anti-Jo1 Ab epitope of HisRS has been suggested to be localized within the first 60 
amino acids near the N-terminal (WHEP domain) (204, 205) even if anti-Jo1 Ab may 
recognize different HisRS epitopes (epitope spreading) (206, 207), disfavoring the 
hypothesis of anti-Jo1 Ab production as result from a cross-reactive antigen (mimicry 
theory). So far, it is not known how the reactivity to different domains/variants of HisRS 
behaves through the disease course and whether Ab against different domains/variants of 
HisRS are associated with specific clinical features of IIM/ASS. Furthermore, it has been 
shown that anti-Jo1 Ab, mainly IgG1 isotype, undergo class-switching and affinity 
maturation, supporting that HisRS-driven specific T cells directly contribute to the 
development of anti-Jo1 Ab (199, 206). Ascherman et al. demonstrated HisRS-induced T-
cell proliferation in peripheral blood and T-cell response was enhanced if HisRS fragments 
were presented by dendritic cells (203). Our research group has found activated CD4+ T cells 
with pronounced Th1 phenotype in bronchiolar alveolar lavage (BAL) fluid and peripheral 
blood in patients with anti-Jo1 Ab and HLA-DRB1*03 genotype, by stimulating T cells with 
a candidate T cell epitope of HisRS, or with the full-length protein. The activation of T cells 
was abrogated by antibodies against DR but not DQ, underlying that an MHC-II restricted 
context is required. Lung derived T cells from BAL fluid compared to blood produced high 
amounts of the pro-inflammatory cytokine IFN-gamma in response to stimulation with 
HisRS protein and one of the HisRS peptides (aminoacids residues 11-23 in the N-terminus 
of the HisRS protein). In addition, anti-Jo1 Ab were found in the BAL fluid and T cells 
surrounding plasma cells were observed in germinal-like structures in lung tissues of anti-
Jo1+ patients but not anti-Jo1- or patients with chronic obstructive lung disease (208). In 
another study aiming at comparing the T cell-receptor (TCR) expression in BAL fluid, 
muscle tissue, and peripheral blood obtained from patients with recently diagnosed myositis 
with and without lung involvement, T cell expansions in CD4+ and CD8+ cells were found in 
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BAL fluid but not in peripheral blood.  Notably, the same TCR expression was observed in 
BAL and muscles of patients with the HLA–DRB1*03 allele and anti-Jo1 antibodies, 
suggesting that the inflammatory process may be driven by T cells with identical antigen 
specificity in lungs and muscles (209).  
All these findings are contributing to the hypothesis of the lung as the site of disease initiation, 
where the break of tolerance towards HisRS may occur for the first time. How the immune 
response perpetuates and involves other tissues, e.g. muscles, needs to be addressed. One 
interesting pathway may involve type 1 IFN which is a known inducer of MHC-I (210). Our 
research group found that anti-Jo1+ sera induced type 1 IFN production in human blood cells 
(211). Given that both MHC-I and type I INF-induced genes expressions are high in muscle 
tissue and peripheral blood of myositis patients (212, 213), one possibility is that anti-Jo1 Ab 
mediate pathogenesis via IFN. In 2012 Howard et al. also showed in vitro that HisRS possess 
chemokine-like properties capable of stimulating lymphocytes, activated monocytes, and 
immature dendritic cells (214). Moreover, enhanced formation and/ or decreased degradation 
of neutrophil extracellular traps (NETs) has been found in the plasma of anti-Jo1+ patients.  
NETs are capable to damage endothelial and epithelial components of various tissues. (215). 
So far, no functional studies on the effects of anti-Jo1 Ab on lung or muscle cells have been 
published. 
In other autoimmune diseases, variations of glycans appended to the IgG Fc-region have been 
suggested to play a role in the pathogenesis, by modulating the immune response. The 
glycosylation status of the Fc-region affects the affinity of antibodies and their capacity to 
interact with Fc" receptors and induce complement activation and cytokine secretion (60). In 
RA, the IgG-Fc glycosylation pattern differs between ACPAs and non-ACPA-IgG and 
changes in the glycans have been reported prior to RA onset (216-218). Low levels of IgG-
Fc galactosylation are known to be associated with high pro-inflammatory status, disease 
activity and severity. Interestingly, agalactosylated ACPAs correlate with response to 
methotrexate in early RA (219). Fc-agalactosylated IgG have been also found in pathologies 
involving the respiratory tract such as sarcoidosis and chronic asthma (220). In patients with 
IIM, more agalactosylated forms of IgG have been found compared to healthy siblings and 
age/sex matched controls (221). The glycosylation status of anti-Jo1 Ab and total IgG present 
in serum of anti-Jo1+/- patients has not yet been explored. 
4.3( Animal models of anti-Jo1 positive ASS 
 
Spontaneous, induced or transgenic animal models of human myositis have failed to fully 
reproduce all the clinical features of human myopathies and in particular the coexistence of 
lung and muscle pathology as in ASS (222, 223). Inoculation of human HisRS protein in 
mice resulted in the production of low levels of anti-Jo1 Ab and presence of inflammatory 
infiltrates only in the muscle which was the site of injection (224). The lack of development 
of specific clinical manifestation in these mice were probably due to production of Ab against 
the human HisRS protein and not to the native murine one. In fact, the attempt of 
immunization of mice strains with the amino-terminal portion of murine HisRS was instead 
followed by the development of high titers of anti-Jo1 Ab and pronounced interstitial lung 
disease, demonstrating that the break of tolerance towards HisRS occurs in a species-specific 
manner (225). In mice immunized with the native HisRS protein, muscle inflammation was 
observed although less prominent than the inflammation in the lungs (225). More recently, 
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MRI was used to study the pattern of muscle inflammation 14 days after immunization with 
the amino-terminal portion of murine HisRS (226). Circulating anti-Jo1 Ab were detectable 
already seven days after immunization and Ab titers correlated with raising CK levels. In 
control mice which were injected only with the adjuvant, CK levels remained at background 
levels, discharging the hypothesis of CK elevation due to the intramuscular injection. 
Inflammatory infiltrates in the perimysial connective tissue, which is a common histological 
finding in DM/ASS, were found in immunized mice in contrast with the pattern of muscle 
inflammation observed in the mouse model of acute muscle necrosis induced by inoculation 
of cardiotoxin (226). Although these animal models give some information that can be 
relevant to understand the pathophysiology of human ASS, we still need detailed molecular 
studies of patients with ASS followed over time to understand the development of immune 




5( Specific background of Papers IV-V 
5.1( Cardiovascular comorbidities in IIM 
 
According to a recent Swedish, nationwide, population-based study on mortality in patients 
with IIM, IIM patients had > 3-fold higher risk to die than the general population. The three 
major causes of death, malignancies, pulmonary and cardiovascular diseases (CVD), were 
similar between the two groups but, contrary to the general population, the highest risk of 
death in IIM patients was seen within the first year after IIM diagnosis and then the mortality 
rate decreased over time (227). This suggests that other mechanisms rather than traditional 
risk factors may contribute to the development of the leading causes to death.  
In other autoimmune diseases like RA and SLE (228-231), the association between 
inflammation and CVD, especially at disease onset, has been largely studied, while limited 
data are available on IIM. One large Canadian cohort of incident PM/DM patients and a 
cohort of gender and age matched adults without PM and DM randomly selected from general 
population were retrospectively followed for 15 years to compare the incidence rate of 
myocardial infarction (MI) and ischemic stroke. The incidence rate of MI and ischemic stroke 
per 1000 person-years was 22,52 and 10,15, respectively, for PM patients versus 5,50 and 
5,58, respectively, for general population. In DM patients the risk of MI was near 3-fold 
higher than in general population while the risk of ischemic stroke was not statistically 
different. Only in PM patients, the risk of both MI and ischemic stroke was highest in the 
first year after diagnosis (232). The risk of acute coronary syndrome (ACS) was also found 
higher, particularly within the first year after diagnosis, in a large Swedish cohort of IIM 
patients (in particular in those with PM and sIBM but not DM), compared to age and sex-
matched general population comparators. While older age accounted for risk factor in both 
patients and comparators, male gender was associated with increased risk of ACS only in the 
general population (233). Focusing on venous thromboembolic events (VTE), deep venous 
thrombosis (DVT) and pulmonary embolism (PE), two population-based cohort studies have 
estimated the risk of VTE in IIM patients compared to the general population, both indicating 
an increased risk shortly after start of follow up from IIM diagnosis. In a Canadian cohort, 
after adjusting for relevant risk factors, the hazard ratio (HR) (95% confidence interval-CI) 
for occurrence of VTE was 7 for PM and 8,39 for DM (234, 235). However, in both studies, 
the incidence rate was not stratified by demographic and clinical characteristics, not helping 
clinicians to identify which patients are at risk and should be carefully screened for VTE risk 
factors. Higher prevalence of smoking, hypertension, diabetes, obesity, dyslipidemia has 
been reported in IIM patients compared to general population (236-240), but it has not yet 
been elucidated whether these CV risk factors are differently distributed in IIM patients with 
or without history of arterial and/or venous TE.  
On a pathophysiologic level, systemic inflammation is thought to promote accelerated 
atherosclerosis (241, 242), one of the possible causes of arterial TE. Diederichsen et al. found 
in patients with PM/DM severe coronary artery calcification (CAC), even though in this study 
CAC correlated with age and smoking rather than myositis (236). With attention on VTE, 
the three components of Virchow triad, which are venous stasis, hypercoagulability, and 
endothelial damage, may be directly affected by IIM. Muscle weakness may contribute to 
venous stasis by reducing mobility. Mechanisms of hypercoagulability and endothelial 
damage are discussed in the next paragraph. 
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5.2( Cross-talk between inflammation and coagulation 
 
Highly regulated biological systems mediate the interaction between inflammatory response 
to injury or pathogens and coagulation pathways. Dysregulation of any of the actors 
maintaining this delicate balance may lead to exacerbation of inflammation and thrombosis. 
In inflammatory conditions, damage-associated molecular patterns (DAMPS), cytokines and 
chemokines determine up-regulation of pro-coagulants such as tissue factor (TF) and TF-
factor VII complex, downregulation of natural anticoagulants, such as proteins C and S, 
moreover platelet activation and suppression of fibrinolysis leading to a hypercoagulable 
state (243). Endothelial cells are activated by pro-inflammatory cytokines with consequent 
up-regulation of adhesion molecules implicated in leukocyte transmigration. Migration of 
leukocytes through endothelial junctions to the site of inflammation is strictly regulated by 
the selectin-dependent activation of !2 integrins on leukocytes, which is responsible of 
tethering and rolling of leukocytes on the vessel wall.  Then, the interaction of leukocyte !1 
and !2 integrins with their receptors on endothelial surface (vascular cell adhesion molecule 
(VCAM)-1 and intracellular adhesion molecule (ICAM)-1) allows a firm adhesion of 
leukocytes before their transmigration (244). Increased serum levels of adhesion molecules 
are found in case of endothelial dysfunction which plays a central role in the cascade of events 
leading both to arterial and venous thrombotic events. Circulating VCAM-1 predicted 
cardiovascular death in patients with acute coronary disease independently of other risk 
factors (245, 246). Soluble ICAM-1 was indicated as predictor of myocardial infarction (247) 
and peripheral artery disease (248) in healthy men. High levels of e-selectin correlated with 
myocardial infarction and carotid artery atherosclerosis (249, 250). On the contrary, low e-
selectin levels have been associated with recurrent venous thromboembolism in the general 
population (251, 252). 
Since 1990s, increased expression of e-selectin, VCAM-1 and ICAM-1 on endothelial cells, 
infiltrating cells in the endomysium and perimysium and sarcolemma of non-necrotic fibers 
has been observed in muscle specimens of patients with PM, DM, sIBM and JDM, although 
with some differences among subgroups (253-256). In a rat model of human polymyositis 
strong expression of ICAM-1 on the sarcolemma of non-necrotic muscle fibers and in the 
endothelium of vessels in the endomysium and perimysium was found to correlate with the 
degree of inflammation in muscle biopsies (257). With respect to myositis disease duration, 
upregulation of VCAM-1 and ICAM-1 has been found both in the untreated early phase and 
despite immunosuppressive treatment, suggesting either premature involvement of adhesion 
molecules in the pathogenesis of IIM or role in perpetuating inflammation (258). Higher 
soluble levels of adhesion molecules have been reported in PM, DM and sIBM patients 
compared to controls (254, 259-261). However, it has not been investigated in IIM patients 
if serum levels of adhesion molecules are different in case of arterial and/or venous TE and 
in relation to patient characteristics, autoimmune profile and traditional CVD risk factors.   
Another factor with an association to TE is the anti-phospholipid antibody (APL), but limited 
information is available on APL in patients with IIM. An association between history of TE 
and APL in patients with IIM has been described in few cases with IIM (262-264). The exact 












The overall aims of this thesis were 1) to increase the understanding of the role of anti-Jo1 
antibodies and HisRS autoantigen in the pathogenesis of the anti-synthetase syndrome (ASS), 
a distinct subgroup of idiopathic inflammatory myopathies (IIM) and 2) to study the impact 
of and the risk factors associated with a life-threatening comorbidity of IIM, the arterial and 




Paper I: To investigate if HisRS is detectable in extracellular compartments (serum) and 
whether levels correlate with anti-Jo1 autoantibodies. To verify if the sequestration of HisRS 
is an epiphenomenon or plays a causal role in the disease. 
Paper II: To investigate if the glycosylation profile of total IgG from anti-Jo1 positive and 
anti-Jo1 negative patients is different and if particular Fc-glycan features are associated with 
specific clinical manifestations. 
Paper III: To address the reactivity and affinity of anti-Jo1 autoantibodies from serum and 
bronchoalveolar lavage fluid (BALF) and associations with clinical data in longitudinally 
followed patients with IIM/ASS. 
Paper IV: To assess the incidence of venous thromboembolic events in patients with IIM in 
comparison to the general population and to identify patient categories at high risk and the 
timing of risk in relation to the diagnosis of IIM. 
Paper V: To assess the contribution of traditional and/or disease-related risk factors and 











































































1( Patient cohorts, data sources, clinical information 
 
With the exception of Paper IV (paragraph 1.4), patients included in this thesis were regularly 
followed at the Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden. 
Classification of IIM was made according to the Bohan and Peter criteria (84, 85) for patients 
included in Paper I-II-III and according to the EULAR/ACR classification criteria for IIM 
(probability threshold of 55%) (89) for patients included in Paper V. Griggs criteria (87)  
were applied for sIBM. The diagnosis of ASS was based on the presence of anti-aaRS 
autoantibodies, plus one of the following features: ILD, myositis, arthritis, Raynaud´s 
phenomenon, fever, or mechanic´s hands (265). Diagnosis of ILD was based on the American 
Thoracic society criteria (266, 267). Imaging (lung x-ray and/or HRCT) and lung function 
tests consistent with the diagnosis of ILD were verified for all patients. Clinical information 
was collected by review of patient medical charts and by extracting data from the Swedish 
Rheumatology Quality Register for IIM (Swemyonet) (268), and the Euromyositis register 
(79).  All patients and controls gave their written informed consent to participate in the 
studies. 
Patient cohorts included in each paper are described below. 
1.1( Paper I 
 
First available serum samples from 357 patients with IIM were selected for the purpose of 
this study. By performing a validate test (immunoprecipitation (IP), Line Blot, Enzyme-
linked immunosorbent assay (ELISA)) for the presence of anti-Jo1 antibodies at least once 
during the disease course, 61 anti-Jo1 positive and 286 anti-Jo1 negative patients were 
identified. Seventy-one out of 357 patients fulfilled the criteria for ASS and 94 out of 357 
presented with ILD. Age at serum sampling, gender and IIM subgroups distribution are 
presented in table 1 of Paper I. Serum samples from 115 age- and gender-matched healthy 
individuals (obtained from the Rheumatology biobank) were also included.  
1.2( Paper II 
 
First available serum samples from 44 patients with IIM, 19 anti-Jo1 positive and 25 anti Jo1 
negative, and 24 age- and gender-matched healthy controls were included. Patients were 
defined as anti-Jo1 positive if they had ever tested positive for anti-Jo1 antibodies by 
standardized immunoassays (IP, Line Blot, ELISA). Information on age, gender, IIM 
subgroups, disease duration between time of diagnosis and time of sampling, extra-muscular 
manifestations, presence of MSAs and/or MAAs, disease activity data (physician and patient 
VAS, MMT-8, MDAAT, CK levels, HAQ), immunosuppressive treatment at time of first 
available serum sample is summarized in Table 2 of Paper II. Sera at different longitudinal 
time points were retrieved from 11 out of 19 anti-Jo1 positive patients and 7 out 25 anti-Jo1 
negative patients (Supplementary Table 1, Paper II). Clinical data collected at time of 




1.3( Paper III 
 
Two cohorts of patients were selected for this study. Cohort 1 is the same as in Paper II. 
Cohort 2 is composed of 10 patients with IIM/ASS, 6 anti-Jo1 positive and 4 anti-Jo1 negative 
patients. The definition of anti-Jo1 positivity is the same as applied in Paper I and II. First 
available serum samples in relation to IIM/ASS diagnosis as well as longitudinal serum 
samples up to 24 years after diagnosis were retrieved from Cohort 1. Matching BALF and 
serum collected at time of diagnosis were available in the biobank from Cohort 2. Serum 
samples from 24 age-and gender-matched healthy controls were also analyzed. More than 60 
variables representing clinical features, laboratory parameters, disease activity and outcome 
measures were collected at time of each sampling. Demographic data of cohort 1 and 2 are 
summarized in Table 1 and Supplementary Table 1, respectively, of Paper III.  
1.4( Paper IV 
A cohort of patients with IIM was identified by using the Nationwide Patient Register, which 
includes non-general practitioner outpatient visits in Sweden since 2001 and inpatient care 
since 1987. To be included in the IIM cohort, each individual had to be age !18 years, have 
had the first ever visit between 2002 and 2011, and a follow-up visit within 1–12 months, 
coded to indicate IIM according to International Statistical Classification of Diseases and 
Related Health Problems, Tenth Revision (ICD-10) codes. The ICD-10 codes used are shown 
in Supplementary Table 1 of Paper IV. The second registered visit was used as the index date 
which corresponds to the date of start of follow up for the patients included in the analysis. 
Because of overlapping ICD-codes between different IIM subgroups, patients were classified 
as affected by DM or by other IIMs. Each patient with IIM was matched with 10 randomly 
selected individuals from the Swedish Population Register (which includes all Swedish 
residents). Matching variables were sex, residential area, and birth year. Each population-
based comparator was required to be alive and living in Sweden at the index date of the 
corresponding patient with IIM. Clinical information on comorbidities (hypertension, 
inflammatory bowel disease, interstitial lung disease, or ischemic heart disease) ever before 
the index date for patients and comparators was retrieved from the Nationwide Patient 
Register. The Prescribed Drug Register was used to capture the occurrence of relevant 
therapies (anticoagulants, hormone replacement therapy, oral contraceptives, antidiabetic 
drugs, methotrexate, glucocorticoids, antihypertensive drugs, and statins 365 days prior to 
and up to 15 days after the index date) in patients and comparators. Since data on dispensed 
drugs were available from 2005 and later, only patients with IIM and general population 
comparators identified from 2005 to 2011 were included in this study. The Cancer register 
was checked to detect all cancers that had occurred in patients and comparators before the 
index date. Baseline characteristics, comorbidities and treatment of patients with IIM and the 
general population cohort are summarized in Table 1 of Paper IV. Each IIM patient or 
comparator was defined as a case if during the follow-up period, starting at the index time, 
the occurrence of a venous thromboembolic event (primary outcome) and in particular of 
deep venous thrombosis and pulmonary embolism (secondary outcome) was verified by a 
visit with corresponding ICD-10 codes and by one prescription for relevant anticoagulants 
within 30 days. The follow-up period ended for patients and comparators at outcome, first 






Amino acid (aa) coverage and molecular weight of HisRS antigens and control proteins utilized in ELISA, 
western blot, and affinity measurements (Paper III) 
ID Antigen aa Molecular weight (Da) 
Biotinylated antigens containing his tag 
HisRS full-length (HisRS-FL, P12081*) M1-C509 62485.0 
WHEP M1-K60 11687.3 
Catalytic domain (CD) K53-E402 43676.0 
Anti-codon binding domain (ABD) T406-C509 16906.3 
Splice variant (WHEP+ABD, SV) # K61-A398 24341.0 
Interleukin 8 (IL-8, P10145*) E21-S99 14183.1 
Sacsin(Q9NZJ4*) M1-K339 43348.8 
IRF4 (Q15306*) M1-E451 56715.8 
Antigens with biotin but no His Tag 
HisRS full-length (HisRS-FL) M1-C509 60019.4 
WHEP M1-K60 9221.6 
Anti-codon binding domain (ABD) T406-C509 14440.7 
*Uniprot. ID   
 
2.2( ELISA (Paper I, Paper II, Paper III, Paper V) 
 
The enzyme-linked immunosorbent assay (ELISA) is a largely used type of enzyme 
immunoassay (EIA) to detect and quantify the presence of proteins in a liquid sample (serum, 
plasma) by using antibodies directed against the protein to be measured. ELISA is based on 
the interaction between antigen and antibody. Samples containing the target protein are added 
on a solid support and the target protein is captured by a specific antibody (Sandwich ELISA). 
Then, the detection antibody is added forming a complex with the antigen. The detection 
antibody can be linked itself to an enzyme or is detected by a secondary antibody conjugated 
with the enzyme. Between each step, a mild detergent solution is used to wash the plate in 
order to remove non-specifically bound proteins or antibodies. Finally, the enzymatic 
substrate is added to produce a visible signal which corresponds to the quantity of the antigen. 
If the target protein in the sample is an antibody, the recombinant antigen for the antibody of 
interest is immobilized on a capture plate via surface adsorption or via capturing antibody 
and incubated with the samples. A secondary antibody (anti-human IgG) is used to detect the 
presence of antibody-antigen complexes. The ELISA plate allows to detect only one protein 
of interest in each well. Analysis of multiple antigens coated in a single assay well is possible 
by using the electro-chemiluminescence immunoassays (ECLIA). ECLIA follow the same 
principles of ELISA: each well is coated with up to ten antigens which are biotinylated to 
attach to specific regions of the well; the samples are added and antibody binding to the plate 
antigens is detected by secondary antibodies which are coupled with a Sulfo-tag molecule; 
the substrate for the Sulfo-tag is added and its conversion, induced by an electric pulse, 
generates chemiluminescence. A high-resolution camera quantifies the ECLIA signal in the 
various sectors of the well and reports the luminescence signal in each well sector 





2.2.1( Measurement of endogenous human HisRS and HisRS-specific (Jo1) antibodies by 
ECLIA (Paper I) 
Levels of human HisRS were measured in serum samples of IIM/ASS patients by using a 
home-made developed ECLIA assay following the Meso Scale Diagnostic protocol. Both 
capture and detection antibodies targeted the N-terminal of HisRS (approximately amino 
acids 1–60 of HisRS) and HisRS quantification was calibrated with highly purified 
recombinant HisRS. An ECLIA was also developed to detect HisRS-specific (Jo1) 
antibodies. The HisRS capture plate was coated with recombinant HisRS and incubated with 
serum samples. Sulfo-tagged goat anti-human IgG (MSD Cat. #R32AJ-1) were used as 
detection antibodies. Antibody levels were compared to standard curves of a mouse 
monoclonal antibody (clone 1C8). Levels were expressed in pM (upper limit of quantitation: 
ULOQ = 2333 pM, lower limit of quantitation: LLOQ = 3.2 pM).  
2.2.2(Detection of HisRS, anti-Jo1 IgG and IgA by ELISA (Paper I, Paper II, Paper III) 
 
HisRS ELISA was used to quantify HisRS protein in the supernatant obtained from human 
muscle cell culture (Paper I). In paper II and paper III, detection in serum and/or in BALF of 
total IgG, anti-Jo1 IgG, total IgA, anti-Jo1 IgA was performed by adding recombinant 
biotinylated full length, domains and variants of HisRS (HisRS-full length (FL), WHEP 
domain, CD, ABD, and SV) at 10 $g/mL to streptavidin-coated 384 well plates. Alkaline-
phosphatase (ALP) monoclonal antibody MT78 (Mabtech) and ALP monoclonal antibody 
MT20 (Mabtech) were used as secondary antibody for IgG detection and for IgA detection, 
respectively. For anti-Jo1 reactivity analysis of total IgG the peroxidase F(ab’2) fragment 
goat anti-Human IgG (Jackson Laboratories) was employed. After the last washing step, 
pNPP substrate for ALP antibody detection or TMB for peroxidase antibody detection 
(Mabtech and Sigma) were added. The reaction with TMB was stopped after 15 minutes by 
adding 1M H2SO4. When using pNPP substrate, the OD (optical density) was measured every 
15 minutes at 405 nm and, when using TMB substrate, the OD was measured one time at 450 
nm (SoftMax Pro version 4.8, Molecular Devices). Anti-Jo1 IgG purified from total IgG 
isolated from a sera pool of IIM/ASS patients was employed as a standard curve in order to 
quantify the antibody levels.  
2.2.3(Detection of adhesion molecules and anti-phospholipid antibodies by ELISA (Paper V) 
 
Soluble adhesion molecules were analysed in serum samples of IIM patients and HC using 
Human ICAM-1/CD54 Allele-specific Immunoassay, Human sVCAM-1/CD106 
Immunoassay and Human sE-Selectin/CD62E Immunoassay (all from R&D Systems Inc. 
USA) based on a quantitative sandwich enzyme immunoassay technique. The results were 
expressed in ng/mL. The anticardiolipin antibodies (IgA, IgG, IgM) and anti-%2-glycoprotein 
I antibodies (IgA, IgG, IgM) were measured in IIM patients by the multiplex immunoassay 
Bioplex 2200 system in accordance with the manufacturer’s instructions (Bio-Rad, Hercules, 
CA, USA) and the routine protocol in the clinical immunology laboratory. They were 
considered positive when !20 U/ml. The term any antiphospholipid antibodies included 




2.3( Isolation of total IgG and anti-Jo1 IgG by development of in-house prepared 
affinity columns 
 
Serum samples of IIM/ASS patients and HC were centrifugated and diluted 1:5 (vol/vol) in 
PBS. Total IgGs from serum were purified on HiTrap Protein G HP columns (GE Healthcare, 
Stockholm, Sweden). IgG was eluted with 0.1 M glycine–HCl buffer (pH 2.7) and the pH 
immediately neutralized with 1M Tris (pH 9). The buffer of eluted IgG was exchanged to 
PBS by dialysis and concentrations measured by nanodrop (ThermoFisher Scientific). To 
prepare the Jo1 affinity column, 1 mg of recombinant HisRS (non-biotinylated) was coupled 
to N-hydroxysuccinimide activated pre-packed sepharose column (size 1 mL, Ref 17071601 
GE Healthcare) according to manufacturer instructions (Isolation protocol of total IgG and 
anti-Jo1 IgG used in Paper II is visualized in Figure 9A).  
2.4( Western blot and dot blot (Paper I, Paper II, Paper III) 
 
Western blot (WB) is an analytical technique which is widely used to detect and semi-
quantify specific proteins in complex protein mixtures. Proteins contained in a sample are 
first denatured and then separated by gel electrophoresis. The electrophoresis membrane is 
incubated with a primary antibody which recognizes and binds the target protein. A 
secondary antibody is added to bind the primary antibody and the targeted protein is 
visualized by various techniques such as chemiluminescence staining, immunofluorescence 
and radioactivity. Dot blot is a simplification of WB method. Proteins to be identified are not 
separated by gel electrophoresis, while the sample is directly applied on the membrane in a 
single spot. Dot Blot is a faster method but it does not provide information on the size on the 
target protein. In Paper I, WB was applied to analyze HisRS, methionyl-tRNA synthetase 
(MARS) and tubulin proteins in cell lysates (intracellular) and in concentrated medium 
obtained from human muscle cell culture by using specific antibodies. Dot blot was used to 
detect HisRS protein as follows. Serum (1µL) was applied to nitrocellulose membranes. Blots 
were probed with monoclonal mouse anti- human HisRS N-terminal (Abcam) and developed 
with a polyclonal goat anti-mouse IgG HRP conjugate (Dako) followed by enhanced 
chemiluminescent detection. In Paper II, samples derived from the IgG purification protocol 
(serum, serum-depleted IgG=protein G flow through (PGFT), total IgG, non-Jo1 reactive IgG 
(Jo1FT) and anti-Jo1 IgG) underwent WB and dot blot to confirm the efficiency of the 
purification protocol (Figure 9 C-D). In Paper III, one microgram of each HisRS protein 
variant (HisRS-FL, WHEP, CD, ABD, and SV) underwent WB. The different membranes, 
each containing a different HisRS protein variant, were individually incubated with anti-Jo1 
IgG from 19 anti-Jo1+ patients, 2 anti-Jo1- patients and 3 healthy controls. Secondary 
antibody rabbit anti-human IgG HRP labelled (sc-2769 Santa-Cruz Biotechnology) was 
employed. Images were acquired and bands were quantified on a ChemiDoc XRS+ System 









Medium was renewed every 2 days, and media was harvested as 0–2, 2–4, and 4–6 samples, 
with three biological replicates per condition. Cells were fixed on differentiation days 2, 4, 
or 6 and stained for myotubes using anti-human myosin antibody; nuclei were stained with 
Hoechst 33342 nuclear stain. The myotube area was analyzed by determining the fusion 
index (calculated as the number of nuclei within the myotube-stained area over the total 
number of nuclei) and the nuclear number per imaging field, with a total of 20 images from 
two biological replicates.  
2.6( T cell activation protocol (Paper I) 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of healthy 
donors by density-gradient centrifugation. T cells were purified using a negative selection 
magnetic kit (StemCell Technologies) following the manufacturer’s instructions. The purity 
of the T cells was > 95%. Activation of T cells was induced on a ninety-six-well flat-
bottomed plates with anti-CD3 antibody (BioLegend, clone UCHT-1) and anti-CD28 
antibody (BD Biosciences, clone CD28.2). T cells were treated with HisRS (0.1 nM). After 
24 h of incubation at 37 °C, the supernatants were collected for ELISA analysis of interleukin 
(IL)-2, IL-10, IL-13, IL-17A, TNF- &, IFN', and IL-9 and Granzyme B levels. For flow 
cytometry, T cells were incubated on ice with an FcR Blocking Reagent (Miltenyi Biotec) 
for 10 min and then stained with anti-CD4 BV510, anti-CD8 APC/ Cy7, anti-CD69-PE/Cy7, 
and anti-CD40L-BV421 (all from BioLegend). Propidium iodide (Miltenyi Biotec) was 
added as a viability marker. Samples were acquired on a MACSquant flow cytometer 
(Miltenyi Biotec) and analyzed with FlowJo software (Tree Star). T-cell checkpoint receptor 
expression experiments were performed with Primity Bio’s surface profiling platform 
(Fremont, CA).  
2.7( Liquid chromatography/mass spectrometry (LC-MS/MS) (Paper II) 
Liquid chromatography/mass spectrometry (LC-MS) is an analytical chemistry technique 
that allows to separate multiple components in a mixture with LC and to provide structural 
identity of the individual components with high molecular specificity (MS). Variations of the 
glycans appended to the different isotypes of IgG obtained from HC, anti-Jo1 positive and 
negative serum samples and from samples enriched for anti-Jo1 antibodies were analyzed by 
LC-MS/MS. Samples were digested with trypsin in duplicates according to previously 
described protocols (216, 271). A in house-developed software (Quanti) (272) was set to 
determine the Fc-glycopeptide profiling for each sample. In addition to Fc-glycan profiling, 
samples were simultaneously subjected to regular peptide sequencing of MS/MS spectra 
(216, 271). 
2.8( Surface plasmon resonance (Paper III) 
Affinity measurements of serum-derived IgG to HisRS-FL from anti- Jo1 positive patients 
were performed using surface plasmon resonance (SPR). The measurements were carried out 
using the Biacore T200 biosensor instrument (GE healthcare) and single cycle kinetics mode. 




3( In vivo methodology 
3.1( Animal studies 
Studies conducted in animals were performed to verify if anti-Jo1 antibodies are responsible 
of muscle and lung injury in vivo after inducing only break of tolerance against HisRS or 
after efficient immunization and tissue challenge. HisRs protein was administered to test if it 
has an immunosuppressive effect. 
3.1.1( Immunization against HisRS 
Either HisRS antigen (200 µg in a 100 µL vehicle volume) or vehicle alone (Sham Vax) were 
injected subcutaneously at two different sites (e.g., flank, base of tail; 100µL per site) in 
female SJL/J mice (The Jackson Laboratory, 8 weeks of age). In the treated group, after 2-
week intervals, 200 µg of antigen in 100 µL vehicle was injected. In independent 
experiments, 7 weeks after the initial immunization, animals were challenged by 
oropharyngeal administration of bleomycin (2 U/kg, Hospira, Lot: B051485AA, lung 
challenge) or intramuscular administration of cardiotoxin (skeletal muscle challenge) (10 µg 
per injection; 50 µL of 0.2 mg/mL solution) in the quadriceps, gastrocnemius and tibialis 
anterior muscles of one side (Sigma Cat. #C9759). Corresponding controls received vehicle 
treatments in the same manner. One week after challenge, mice were placed in a chamber 
containing 2% isoflurane. The latency of anesthetic was monitored and a longer time of 
latency indicated an impaired gas exchange and thus impaired lung function. Muscle function 
was assessed 6 days after challenge by evaluating the degree to which mice splayed the rear 
legs when picked up by the tail. In healthy animals, rear legs were extended far from the body 
(score = 0), whereas in animals with impaired muscle function, the foot remained close to the 
body (score = 2). Twelve days after lung challenge or 7 days after muscle challenge, serum 
and BALF were harvested for measuring HisRS and antibody titers; tissues were collected, 
fixed, processed to produce slides, stained with hematoxylin and eosin (H&E) and scored by 
a pathologist. Mediastinal lymph nodes were collected for immunophenotyping.  
3.1.2( Bleomycin-induced lung injury 
Starting from 8 days after intratracheally administered bleomycin in PBS saline at a dose of 
3mg/kg in a volume of 50 µL per animal using a Microsprayer®, female C57bl/J mice 
received intravenously mouse-HisRS at a dose of 3 mg/kg once daily from day 8 to day 21. 
Dexamethasone was orally administered to the mice at doses of 0.25mg/kg once daily from 
day 0 to 21. Four or 5 randomly selected mice underwent HRCT scans and images were 
analyzed by Onis Viewer (DigitalCore, Japan). Lung density was determined in two sections 
and eight regions of interest. BALF was collected and centrifuged, and the supernatant was 
collected and stored until biomarker analysis. Lungs were harvested, processed to produce 
slides and stained with Masson’s trichrome. The degree of pulmonary fibrosis was evaluated 








Figure 10 Schematic representation of bleomycin lung injury model. BLM, bleomycin. DXM, 
dexamethasone. VEH, vehicle. HRCT, high resolution computer tomography. BAL, bronchoalveolar lavage 
fluid 
3.1.3( Cardiotoxin-induced myositis 
Cardiotoxin extracted from Naja mossambica mossambica was injected into the tibialis 
anterior, quadriceps and gastrocnemius muscles of one mouse hind limb (Sigma Cat. #C9759; 
10 µg/injection). The contralateral limb was injected with saline and served as a control. 
Tissues were harvested 7 days after cardiotoxin administration and were then stained with 
hematoxylin and eosin.  
3.1.4( Statin-induced muscle injury 
Ten-week-old female Sprague-Dawley rats (n = 8 per group) were treated with cerivastatin 
for 7 days and then every other day. On days 6–14, HisRS was administered intravenously at 
doses of 0.3, 1, or 3mg/kg. In parallel, negative controls received the vehicle. All rats were 
euthanized on day 15, and hamstring muscles were harvested, fixed, processed to produce 
slides, and stained with H&E. A pathologist blinded to the treatment groups assessed 
myofiber degeneration/ necrosis. A subjective, semiquantitative scoring system was utilized 
by the pathologist: 0 = no significant lesion; minimal change = 1; mild change = 2; moderate 
change = 3; and marked change = 4. Subsequently, the sections were quantified for necrotic 
myofibers and the number of nuclei per 20x field using imaging software at aTyr Pharma by 
a scientist blind to treatments. The number of nuclei was measured as an indication of 























Figure 11. Schematic representation of statin muscle injury model. VEH, vehicle. H&E, hematoxylin and 
eosin staining 
3.1.5( Transcriptional profiling of muscle tissue 
Hamstring tissue was excised from treated and control rats. Transcriptional profiling of 
muscle tissue was performed by quantitative polymerase chain reaction (qPCR). Expression 
of muscle-associated (Acta1, Actb, Acvr2b, Adrb2, Agrn, Akt1, Akt2, Atp2a1, B2m,Bcl2, Bhlhe41, Bmp4, 
Camk2g, Capn2, Capn3, Casp3, Cast, Cav1, Cav3, CD138, CD8b, Cryab, associated Cs, CTGF, Ctla4, Ctnnb1, 
CYCS, Dag1, Dars, Des, DLEC, Dmd, Dysf, Emd, Fbxo32, FOXO1, Foxo3, FSP1, Gapdh, GARP, Gars, GITR, 
Gpr44, Gusb,, Hars, Hars2, Hk2, Hprt1, Hsp90ab1, Igf1, Igf2, Igfbp3, Igfbp5, Ikbkb, Il17ra, Il17rb, Il17rc, 
Il17re, Ldha, Lep, Lmna, LTA, Mapk1, Mb, Mbnl1, Mef2c, Mstn, Musk, Myf5, Myf6, Myh1, Myh2, Myod1, 
Myog, Myot, Neb, Nos2, Pax3, PAX6, PAX7, Pdk4, Ppp3ca, PRF1, Ptprc, Qars, Rhoa, Rora, Rplp1, Rps6kb1, 
Runx3, Sgca, TRIM63, Utrn) and immune-associated genes (B2m, Ccl20, Ccl5, Ccr4, CCR5,Ccr6, 
CD117, CD11A, CD11b, CD127, CD14, CD18, CD19, CD20, CD25, CD28, CD29, CD3, CD4, CD45R, 
CD49D, CD8a, associated CD8b1, COL1A2, COL3A1, CXCR3, EBI3, F4/80, Fasl, FGF1, Fgf2, Foxp3, FZD7, 
Gapdh, Gata3, Gata4, Hars, Hsp90ab1, ICAM1, ICOS, Ifgr, IFNa1, IFNg, IKZF2, IL10, IL12A, IL12B, 
IL12RB1, IL12RB2, IL13, IL15, IL15RA, IL17a, Il17c, Il17d, Il17f, IL18RA, Il1b, IL1r, Il2, Il21, Il22, Il23a, 
Il23r, Il25, Il27, Il2ra, IL33r, Il4, Il4ra, IL5, Il6, Il6ra, Itgax, MAF, MCP1, MIF, MMP1, MMP3, Mmp9, NCAM, 
Nfkb1, NK1.1, Rig1, RORC, Stat1, Stat3, Stat4, Stat5a, Stat6, TBX21, Tgfb1, Tgfb3, Tnf, VCAM1, WNT7a ) 
was analyzed and compared between groups. 
4( Statistical analysis 
 
Continuous variables with normal distribution were presented as means with standard 
deviations (SD), while variables that violated normality were presented as medians with 25-
75th percentiles [25-75th] or as medians with inter-quartile range (IQR). Normal distributed 
variables between two distinct groups were compared using the two independent sample t test 
while variables collected at different time points from the same group were compared by 
performing the paired t-test or the Wilcoxon rank sum test. Comparison of categorical 





















Kruskal-Wallis (correction for multiple comparisons by Dunn’s test) or Mann-Whitney tests 
were employed when quantitative variables were compared among all groups or between two 
groups, respectively. In Paper I, Spearman correlation was applied between serum levels of 
circulating HisRS and anti-HisRS antibodies. P<0.05 denoted significant difference. In Paper 
II and in Paper III, multivariate modelling using Principal Component Analysis (PCA) and 
Orthogonal projections to latent structures discrimination analysis (OPLS-DA) was 
performed using SIMCA 15.0 (Umetrics, Sweden) following mean centering, log 
transformation and UV scaling. Model performance was reported as the cumulative 
correlation R2X[cum], and predictive performance – as Q2[cum] based on seven-fold cross 
validation. In Paper IV crude incidence rates were calculated by dividing the number of 
events during follow-up by the corresponding person-years at risk. All incidence rates are 
given as the number of events per 1,000 person-years. The incidence rates were calculated in 
men and women separately, as well as based on subgroups of IIM, age group at diagnosis, 
stratified by cancer status at the index date. The overall rate difference and 95% confidence 
intervals (95% CIs), adjusted for age and sex, were also calculated using an additive Poisson 
model. Cox proportional hazards models were constructed to estimate hazard ratios (HRs) to 
compare the incidence rate of VTE, DVT and PE in patients with IIM and the general 
population. All models were adjusted for age at the index date as a continuous variable, birth 
year, year of IIM diagnosis (corresponding in matched general population comparators), sex, 
and residential area. Cumulative incidences of VTE at 1, 5, and 8 years after start of follow-
up were estimated and plotted for IIM and the general population, taking the competing risk 
of death into account, after performing a competing risk analysis using the Fine and Grey 
method. A sensitivity analysis with start of follow up 30 days after the index date was 
conducted to decrease the risk of having hospitalization as detection bias.  In Paper V logistic 
regression models were fitted with TE as the dependent variable. Covariates of interest were 
assessed in univariate regression models, and covariates that were significant were entered 
as independent variables in multivariable logistic regression models. All statistical analyses 
were performed with Statistical Package for the Social Sciences (SPSS, version 22.0, IBM 
software, USA), or GraphPad Prism version 8 (La Jolla, USA), or SAS software, version 9.4, 
R software, version 3.3.3, and STATA IC software, version 11.2.  
5( Ethical approval  
All studies in this thesis were approved by the Regional Ethical Committee of Stockholm and 
performed according to the Declaration of Helsinki guidelines on studies with human 
subjects. Subjects provided written informed consent. Studies conducted in animals were 
performed following prior approval of local institutional animal care and use committees 
(IACUCs) at aTYR Pharma, San Diego, U.S. and were in accordance with accepted standards 







RESULTS AND DISCUSSION 
1( HisRS is present in circulation in healthy individuals and its sequestration may 
contribute to the development of ASS (Paper I) 
Extracellular HisRs or HARS circulates in healthy individuals and levels are reduced in 
presence of anti-HisRS antibodies 
Secretion of HisRS from cells (195) has been reported only in vitro experiments. In study I 
we developed a sensitive ECLIA, calibrated with recombinant HisRS, to detect levels of 
HisRS in vivo, i.e. in serum of patients with IIM with (n=61) or without anti-Jo1 antibodies 
(n=286) and healthy individuals (NHV, normal human volunteers, n=115). Free HisRS was 
found in 98% of NHV and, in contrast, was undetectable in 84% of 61 patients with anti-Jo1 
antibodies (p<0.0001). In the group of anti-Jo1 negative patients (n=286), levels of free 
HisRS were significantly higher than in NHV. Levels of circulating HisRS did not differ 
between distinct IIM subgroups (PM, DM, JDM, sIBM). Instead, when stratifying the patient 
according to the presence or not of ILD, levels of HisRS were significantly lower in patients 
with ILD (n=94) compared to those without (n=209, p<0.0001). Presence of HisRS in 
circulation was also confirmed by Dot Blot. Levels of two other aaRS, asparaginyl-tRNA 
synthetase (NARS, the autoantigen target KS) and glycyl-tRNA synthetase (GARS, the 
autoantigen target EJ) were also detected by ECLIA in circulation of both NHV and IIM 
patients. Interestingly, no differences in levels of NARS and GARS were observed between 
NHV and patients and among IIM subgroups with or without anti-Jo1 antibodies or ILD. A 
quantitative ECLIA, calibrated with a commercially available N-terminal HisRS monoclonal 
antibody, was developed to measure the concentration of anti-HisRS antibodies and the 
results were compared with the commercially available assay used for analysis of anti-Jo1 
status in the clinic. The ECLIA confirmed the presence of anti-HisRS antibodies in 51/61 
anti-Jo1 positive patients and 8/286 anti-Jo1 negative patients. A negative correlation was 
observed between anti-HisRS autoantibody levels in serum with circulating levels of free 
HisRS (Spearman correlation r = (0.6244; p<0.0001).  
The presence of HisRS in healthy individuals raises the question whether HisRS is secreted 
from cells to exert a physiological function extracellularly beyond the known intracellularly 
role of protein synthesis. Higher levels of free HisRS in anti-Jo1 negative patients may 
suggest that the physiological secretion in circulation is increased in inflammatory 
conditions, but the cellular source is unclear. Instead, in anti-Jo1 positive patients HisRS is 
likely bound to anti-Jo1 antibodies explaining why levels are undetectable.  
Human muscle cells secrete HisRS 
Muscle inflammation is one of the clinical manifestations characterizing the anti-Jo1+ ASS. 
We observed that primary human skeletal muscle myoblasts could release HisRS in the 
culture medium with increased amounts during differentiation into myotubes. Levels of 
HisRS in culture medium were detected by ELISA and confirmed by WB. The release of 
HisRS was specific since the control proteins, MARS and tubulin, were not found in culture 
medium, but only in cell lysates. Thus, cell lysis seems not to be responsible for HisRS 
secretion from muscle cells. IGF-1 was used a known modulator of muscle cell growth and 
regeneration. The release of HisRS in culture medium increased upon stimulation with IGF-
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1.  This finding is consistent with the previous demonstration of higher expression of HisRS 
by regenerating muscle fibers and may also justify the high levels detected in serum from 
anti-Jo1- patients (202). Possible downstream effects of HisRS secreted in the muscle 
environment should be addressed in future studies.  
Break of tolerance to HisRS is not enough to cause obvious lung or muscle inflammation in 
mice models 
The tolerance to endogenous HisRS was efficiently disrupted in different strains of WT mice 
by immunizing mice with murine full-length (FL) HisRS and WHEP. High titers of anti-
HisRS antibodies and corresponding undetectable levels of free HisRS were found in both 
BALF and serum of immunized mice. Antibody levels were significantly more elevated in 
mice immunized with the WHEP domain compared to those immunized with the FL-protein, 
highlighting the WHEP domain as the major epitope of the antibody reactivity. No obvious 
muscle or lung inflammation was observed in immunized mice compared to control mice. 
However, upon external induction of tissue-specific damage, by injecting cardiotoxin in the 
skeletal muscle or by administering bleomycin in the lungs, the degree of immune 
engagement with consequent muscle damage and lung injury was significantly exacerbated 
in immunized mice than controls. Lung function, assessed by measuring the time of latency 
in response to inhaled anesthetic isoflurane, was more impaired in mice with circulating anti-
HisRS than controls. In addition, 12 days after bleomycin challenge, the mediastinal lymph 
nodes of immunized mice had increased levels of activated CD4+ and CD8+ T cells.  
HisRS has in immunomodulatory effect in vitro 
In vitro effects of recombinant HisRS were investigated on T cells isolated from human blood 
of 8 healthy donors. Freshly resting T cells were not affected by HisRS, while activation of 
CD4+ and CD8+ T cells by anti-CD3 or CD8 antibodies was inhibited by HisRS, as 
demonstrated by less release of inflammatory cytokines, cell-surface markers and Granzyme 
B. The inhibition of T cells was robust already at sub-nM concentrations of HisRS, but was 
abolished upon removal of the N-terminal WHEP domain. In addition, HisRS treatment 
modulated the expression of immune checkpoint receptors specifically on activated T cells. 
Our findings are in contrast with the work of Howard et al. which showed in vitro that HisRS 
possess chemokine-like properties capable of stimulating lymphocytes, activated monocytes, 
and immature dendritic cells (214). Moreover, we also demonstrated in a previous published 
work (208) that lung derived T cells from BAL fluid of anti-Jo1+ patients compared to blood-
derived T cells of anti-Jo1+ patients produced high amounts of the pro-inflammatory cytokine 
IFN-gamma in response to stimulation with HisRS protein, and in particular with one of the 
HisRS peptides (residues 11-23 within the HisRS protein, located in the WHEP domain). 
Whether the source of T cells (blood of healthy donors in Paper I and BALF from anti-Jo1+ 
patients in (208)) accounts for the difference in the results needs to be further elucidated.  
HisRS has therapeutic activity in in vivo inflammatory disease models 
Administration of murine HisRS 8 days after the induction of lung injury with bleomycin 
reduced the degree of lung fibrosis as shown by CT scans, and as well of lung immune 
infiltration and of the release of cytokines in BAL. Daily administration of cerivastatin caused 
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severe skeletal muscle damage and required euthanasia at day 14. In contrast, rodents treated 
with HisRS from day 6 showed less morbidity and better survival than controls in a dose- 
related manner.  
To summarize, in Paper I we demonstrated that extracellular HisRS circulates in healthy 
individuals but is reduced or absent in anti-Jo1 positive patients. Levels of free HisRS were 
in fact inverse correlated with the levels of anti-HisRS antibodies. Our data showed that 
HisRS probably has an immunoregulatory function when secreted outside cells. In vitro, 
HisRS inhibited T cell activation and it had, at least in mouse, immunosuppressive effect in 
bleomycin and statin induced inflammatory models. On the contrary, the degree of 
inflammation in lungs and muscle was exacerbated in mice with high titers of anti-HisRS 
antibodies. Therefore, we hypothesize that the sequestration of HisRS and, specifically, of 
the WHEP domain is a major contributor to the pathogenesis of ASS. However, we cannot 
rule out that immune complexes of anti-Jo1 antibodies and HisRS have independent 
pathogenic capacities. So far, no functional studies on anti-Jo1 antibodies have been 
published.  
2( Anti-Jo1 positive patients exhibit a characteristic IgG-Fc and anti-Jo1 IgG glycan 
profile (Paper II) 
Total IgG were isolated from 19 anti-Jo1+ and 25 anti-Jo1- patients as well as from 24 HC. 
Anti-Jo1 IgG were isolated from a pool of serum collected at different time points from 11 
anti-Jo1+ patients. Total IgG concentration among serum proteins was similar between IIM 
patients and HC. Half of the glycans appended to the Fc region of IgG1 antibodies of IIM/ASS 
patients were significantly different from those found in HC (p < 0.05), showing in particular 
a decrease in galactosylation. No significant differences were observed in the glycan profile 
of IgG2 and IgG3 isotypes between patients and HC. Decrease in galactosylation (major 
agalactosylated form FA2) is known to be associated to inflammatory conditions and to 
factors like age, gender and heritability. Therefore, we tested if the unchanged FA2 of IgG2 
(FA2_2) could be used as an intraindividual control of the change in FA2 of IgG1 (FA2_1). 
The logarithm (FA2_1/ FA2_2) was used as a factor to distinguish patients from HC. 
Receiver Operating Characteristic (ROC) curve analysis of log (FA2_1/ FA2_2) generated 
an area under the curve (AUC) of 79±6% when comparing IIM/ASS patients to HC. The 
AUC went up to 88±6% for anti-Jo1+ patients and for those with ILD, independently of the 
anti-Jo1 status. The AUC decreased to 72±8% for anti-Jo1- patients. By comparing the 
different glycan features according to the sum of galactosylated )[G], sum of agalactosylated 
)[aG], sum of afucosylated )[aF], sum of bisected )[B], and sum of sialylated )[S] forms, 
IgG1 and IgG2 isolated from anti-Jo1+ patients presented lower abundances of bisected and 
afucosylated glycopeptides compared to IgG from anti-Jo1- patients. Anti-Jo1 autoimmune 
reactive IgG (enriched from the IgG from the anti-Jo1 positive patients) was also screened 
for glycan profile and compared intra-individually to the IgG prior to anti-Jo1 enrichment 
and to the remaining non-anti-Jo1 specific IgG following enrichment (termed flow through, 
FT). Anti-Jo1 IgG showed a similar but enhanced profile of the characteristics observed in 
total IgG from anti-Jo1+ patients. Anti-Jo1 IgG were generally less bisected, less 
afucosylated and more agalactosylated compared to the total IgG from anti-Jo1+ patients and 
subsequently compared to the IgG from anti-Jo1- patients and the HC.  Multivariate statistical 
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modelling (MVA) was performed to understand if Fc-glycan features would correlate with 
patient clinical features and protein data obtained from the IgG enriched samples. Bisected 
and afucosylated forms negatively correlated with anti-Jo1+ patients while agalactosylation 
status factor (log[FA2_1/FA2_2]) was associated with anti-Jo1 positive status, confirming 
the results of the univariate analysis. Among clinical features, ASS, ILD, presence of MSAs 
and higher MMT8 correlated positively with presence of anti-Jo1 antibodies.  Among 
proteins, lysozyme, thrombospondin, plasminogen, CD5 antigen like protein, IgD, the 
conserved lambda chain 2, one kappa variable chain, complement factor H related protein 
and platelet factor 4 correlated with anti-Jo1+ status.  
In conclusion, our study showed that both total IgG and specifically anti-Jo1 IgG from 
IIM/ASS patients display a pro-inflammatory Fc-glycan profile (i.e. agalactosylation) which 
is overrepresented in patients with ILD. The majority of patients with ILD tested positive for 
anti-Jo1 antibodies but ten out or 28 with ILD were anti-Jo1-. The hypothesis is that the 
agalactosylated features of ASS/IIM IgG (and anti-Jo1-IgG) are enhanced due to underlying 
lung disease related mechanisms in these patients, as suggested by evidence of the possible 
immunological role of IgG Fc-glycans in the respiratory tract in other lung pathologies such 
as sarcoidosis, severe asthma and lung cancer (220, 274). Furthermore, anti-Jo1 IgG 
specifically presented lower abundance of bisected and afucosylated forms as also observed 
in ACPA (216). These glycopeptides are known to increase IgG affinity to Fc'RII and III 
receptors, potentially resulting in more potent antibody dependent cell-mediated cytotoxicity 
(ADCC) (275, 276). Fc-glycan characteristics of anti-Jo1 IgG positively correlated with 
proteins involved in inflammatory processes, including C-reactive protein. This highlights 
the close link between the glycosylation pattern of IgG and the inflammatory responses and 
supports the hypothesis that the autoantibodies have a role in the pathogenesis.  
3( Anti-Jo1 antibodies with high affinity and reactivity to different HisRS variants and 
domains appear early in the IIM/ASS disease and correlate with lung and joint 
involvement (Paper III) 
Reactivity profile against HisRS of serum and BALF-derived anti-Jo1 autoantibodies 
 
IgG isolated from first available serum sample in relation to diagnosis of IIM/ASS collected 
from 19 anti-Jo1+ patients displayed stronger reactivity against the HisRS-FL and the two 
splice variants (WHEP domain and SV) in comparison with the ABD and CD domains 
(p<0.05). Sixteen of 19 anti-Jo1+ patients showed reactivity to all HisRS antigens, while one 
patient showed exclusive binding to ABD and SV and two patients presented no reactivity 
against any of the HisRS antigens. The ELISA and WB results demonstrated that anti-Jo1 
antibodies recognize both conformation-dependent (ELISA) and -independent epitopes 
(WB), with a strong preference for the WHEP and SV regions. Anti-Jo1- and HC did not 
show reactivity towards HisRS-FL or any of the HisRS-variants/domains. In matching BALF 
and serum samples the highest IgG and IgA reactivity was found against HisRS-FL for 
patients with anti-Jo1+ IIM/ASS. No reactivity was registered in matching BALF and serum 




Anti-Jo1 IgG reactivity through the disease course of anti-Jo1+ patients 
IgG were isolated from longitudinal serum samples collected at different time points from 
16/19 anti-Jo1+ IIM/ASS patients up to 24 years after diagnosis. At time of diagnosis, anti-
HisRS-FL, anti-WHEP and anti-SV IgG recorded higher reactivity levels in comparison to 
anti-CD and anti-ABD IgG. Interestingly, similar reactivity levels were found in three anti-
Jo1+ serum samples collected before diagnosis. Three years after diagnosis, median anti-
HisRS-FL IgG reactivity levels were still as high as at diagnosis, while the reactivity against 
WHEP and SV registered a ~3-fold decrease. The reactivity levels against CD and ABD 
decreased between 6 to 3-fold already one year after diagnosis, remaining low thereafter. 
Through the disease course, median antibody concentrations fluctuated over time and, in 
general, the reactivity towards the different HisRS antigens changed simultaneously. 
Administration of Rituximab, a monoclonal antibody directed against CD-20 in B cells, in 9 
of 16 patients did not result in homogeneous decrease of reactivity levels against the different 
HisRS variants and domains. 
High levels of anti-HisRS antibodies correlate with lung and joint involvement in anti-Jo1+ 
patients 
On the basis of the autoantibody levels targeting HisRS-FL  in the first available sample close 
to the time of diagnosis, patients were stratified into low to moderate (n=8) or high anti-HisRS-
FL reactivity (n=11). Muscle disease activity did not statistically differ between those with low 
to moderate or high anti-HisRS-FL reactivity. On the contrary, anti-Jo1+ IIM/ASS patients with 
high anti-HisRS-FL antibody levels were more likely to be diagnosed with ILD, ever through 
the disease course (100% compared to 63% for the anti-Jo1+ patient group with low to moderate 
anti-HisRS-FL IgG levels and 36% for anti-Jo1- group). The pulmonary function (median 
values of forced vital capacity (FVC), total lung capacity (TLC) in the low to moderate anti-
HisRS-FL reactivity group (FVC 51% and TLC 54%) was significantly lower compared to 
both anti-Jo1+ with high anti-HisRS-FL levels (FVC 67%, TLC 70%) and anti-Jo1- (FVC 81%, 
TLC 76%, p<0.05). Interestingly, the group with low to moderate anti-HisRS-FL titers had 
higher percentage of smokers. The group with high anti-HisRS-FL antibody levels presented a 
higher frequency of arthritis (73%) in comparison to the low to moderate, and negative sub-
groups (38% and 28%, respectively). Skin manifestations were recorded more frequently in 
anti-Jo1+ patients with low to moderate levels and anti-Jo1- patients (38% and 36%, 
respectively) compared to the 18% of patients with high anti-HisRS-FL response. 
These findings were strenghthened by the results generated by the multivariate analysis which 
showed that the anti-HisRS reactivity data together with anti-synthetase syndrome, anti-SSA 
positivity, presence of MSAs and arthritis strongly correlated with both anti-Jo1+ and ILD+ 
status, beeing ILD+ status independent of anti-Jo1 status.  
Inverse correlation between BALF anti-HisRS IgG levels and pulmonary function parameters 
 
A negative correlation was found between several pulmonary function measures (vital 
capacity (VC), FVC, TLC, and forced expiratory volume in 1 second (FEV1) and both BALF 
levels of IgG anti-WHEP and anti-CD, p<0.05). On the contrary, BALF anti-WHEP and anti-
CD IgG as well as anti-HisRS-FL and anti-SV IgA positively correlated with the BALF’s 
cell concentration and the number of eosinophils (p<0.05). The multivariate data analysis 
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showed that both the anti-HisRS reactivity data from IgG and IgA as well as eosinophils and 
mast cells correlated strongly with anti-Jo1+ and ILD+ status. Inversely, higher levels of VC, 
FEV1, TLC, FVC, diffusing capacity for carbon monoxide (DLCO), CD4:CD8 and 
macrophages correlated prominently with anti-Jo1- and ILD- patients.  
Anti-Jo1+ IgG display high affinity already at diagnosis of IIM/ASS!
Surface plasmon resonance (SPR) was applied to measure the binding profiles of serum-
derived IgG to HisRS-FL, close to diagnosis, from the 19 anti-Jo1+ patients. Average kinetic 
constants could be determined for 14 of the patients and in all cases high average affinity 
profiles were observed (calculated AveKD close to 1 nM). 
To summarize, in this study, we found that reactivity levels of IgG and IgA isolated from 
BALF and serum of anti-Jo1+ patients are high already at time of diagnosis and in some cases 
even before diagnosis, generally decreasing thereafter. Highest reactivity was registered 
against the full length HisRS and the HisRS splice variants WHEP and SV. Moreover, IgG 
against HisRS-FL displayed high affinity already at time of diagnosis. Patients with high 
reactivity levels towards HisRS-FL were more more frequently affected by ILD and arthritis, 
but less likely to have skin rash. Noteworthy, IgG anti-WHEP reactivity in BALF correlated 
with poor pulmonary function. Our results add to previous attempts of epitope mapping 
performed by using linker mutagenesis and restriction enzymes, or linear peptide design (36, 
37, 277-281). We have, instead, investigated IgG and IgA reactivity against naturally 
occurring folded HisRS variants by ELISA and WB and we could demonstrate that anti-Jo1 
antibodies recognized both conformational and non-conformational epitopes within HisRS. 
Highly reactive and high affinity anti-HisRS antibodies, especially towards the WHEP 
domain, at time of and even before diagnosis, support the hypothesis that autoimmunity 
against HisRS, driven by exposure to HisRS autoantigen, might be initiated before diagnosis 
of IIM/ASS. In addition, the positive correlation between high reactivity levels of anti-HisRS 
antibodies and ILD as well as the significant correlation between anti-WHEP reactivity in 
BALF and poor pulmonary function suggest the lung as a potential site of immune activation.  
4( Patients with IIM are at high risk of arterial and venous thrombosis especially close 
to diagnosis (Paper IV and Paper V) 
Arterial and venous thrombotic events are a leading cause of death in patients with IIM. A 
better understating of the factors contributing to the development of this life-threatening 
comorbidity is needed to try to prevent that from happening. In Paper IV, we assessed the 
incidence of venous thromboembolic events (VTE) in patients with IIM in comparison to the 
general population and we aimed to identify patient categories at high risk and the timing of 
risk in relation to the diagnosis of IIM. In Paper V, we investigated whether and which 
traditional and/or disease-related risk factors and biomarkers are linked to arterial and venous 
thrombotic events in patients with IIM. 
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The absolute and relative risk of VTE is significantly higher in IIM patients than in the general 
population (Paper IV) 
After excluding both patients and general population comparators presenting VTE before the 
index date, 440 patients with IIM and 4,459 comparators were included in the analysis. The 
proportion of women and men, the mean age at start of follow-up, and the education level 
were similar in patients with IIM and the general population. Comorbidities prior to the index 
date were more common in IIM patients than comparators and IIM patients were more often 
treated with methotrexate, glucocorticoids, antidiabetic drugs, and statins around the period 
of the index date. Prescription of anti-hypertensive drugs was instead more common in 
general population comparators. Median (IQR) follow-up in both cohorts was 4.2 (3.2) years. 
Seventy-nine patients with IIM (18%) and 305 comparators in the general population (7%) 
died, while none of the patients with IIM and 34 comparators of the general population 
(0.1%) emigrated from Sweden during follow-up. Twenty-eight patients in the IIM cohort 
(6.6%) and 48 comparators of the general population (2.0%) experienced a first-time VTE 
during follow-up; in the IIM cohort, 15 (54% of all events) were PE events and 13 (46%) 
were DVT, and in the general population, 19 (40%) were PE events and 29 (60%) were DVT. 
The crude incidence rate of VTE was 16.2 (95% CI 4.3, 28.2) per 1,000 person-years in 
patients with IIM, and 2.4 (95% CI 0.9, 3.8) per 1,000 person-years in the general population. 
In IIM patients but not in the general population the incidence rate was higher in women than 
in men. Among IIM subgroups, DM (diagnosed in 35% of IIM patients) was more associated 
with VTE than the other subgroups. There was a tendency in both patients and comparators 
of increasing rate with ageing. In comparators but not in patients a lower level of education 
was associated with higher incidence rate of the outcome. Diagnosis of cancer before the 
index date conferred to IIM patients higher likelihood to present with VTE. After adjusting 
for age, sex, and residential area, the overall HR of VTE comparing the IIM cohort to the 
general population was 7.81 (95% CI 4.74, 12.85). Other variables including death as 
competing risk did not alter this result. The increased relative risks could be seen in all 
subgroups of IIM, in all age groups, in all education levels, and in both women and men with 
IIM compared to the general population. When we stratified by time since diagnosis, we 
noticed an increased incidence rate and relative risk of VTE in the first year of diagnosis with 
an incidence rate of 39.2 (95% CI 20.7, 57.7 per 1,000 person-years) and HR of 26.6 (95% 
CI 10.4, 68.0). On the contrary, in the general population cohort, the incidence rate was very 
low within the first year of follow-up (incidence rate 1.8, 95% CI 0.6, 3.1) and increased 
slowly with time.  
To conclude, in this study we observed that the incidence rate of VTE was significantly 
higher in IIM patients than in the general population, especially during the first year after 
diagnosis. The HR was almost eight times more elevated in IIM patients than in general 
population and remained that high even after adjusting for education level, comorbidities, 
cancer, treatment at baseline and competing risk of death. The risk was even more elevated 
in patients with a history of cancer, in patients with DM, or in those with age !72 years. Our 
findings were congruent to the results from a Canadian cohort of patients with IIM (234) and 
with a previous publication from Sweden (235).  
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Lower e-selectin levels were associated with a higher risk of presenting with arterial and/or 
/venous thrombotic events (Paper V) 
 
The prevalence of arterial and/or venous TE was retrospectively assessed in a large cohort of 
patients with IIM (n=246). TE occurred up to 30 years after the year of IIM diagnosis with 
peak of prevalence within the first 5 years after IIM diagnosis in 21% of IIM patients. PE 
was the most frequent event followed by DVT and myocardial infarction. Among 
demographic and clinical variables, only age at the time of IIM diagnosis was significantly 
different between cases and comparators. Cases were older than comparators and age at 
diagnosis was an independent risk factor for TE in the investigated IIM cohort. A patient with 
IIM had a 3.5% increased chance of having TE per each year of age (Exp B 1.04, 95% CI 
1.01-1.06, p=0.004). Even if not significant, men were more prevalent in cases than 
comparators as demonstrated in the general population (282, 283). Patients with reported 
venous TE were more likely to be affected by dermatomyositis and testing positive for MSAs, 
while the arterial group was more often diagnosed with polymyositis. Among comorbidities, 
only essential hypertension was found more often in cases (22/51, 43%) than comparators 
(49/193, 25%), p=0.01. Diabetes, dyslipidemia, history of smoking and/or malignancy were, 
instead, equally distributed between the two groups. Malignancy diagnosed before the 
occurrence of TE was more common in cases with reported only venous events than those 
with history of exclusively arterial events. CK and CRP levels were used as proxies for 
disease activity and did not differ neither between cases and comparators nor between the 
arterial and venous group. IMACS disease activity core set measures were available at the 
time of 34/69 thrombotic events. The mean MMT-8 value and HAQ score were both low, 
indicating that reduced physical activity due to inflammatory myopathy together with 
functional impairment in IIM patients could potentially be a risk factor for developing TE. 
In addition, at the time of TE the mean dosage of prednisolone was higher than 10 mg/day 
indirectly suggesting that IIM patients did not have low disease activity. Regarding possible 
biomarkers predicting TE in patients with IIM, we analyzed serum levels of aPL at the time 
of IIM diagnosis and we found that only 6% of the IIM cohort tested positive for aPL 
antibodies, discarding a possible contribution of aPL in the development of TE in IIM 
patients. We also analyzed at the time of IIM diagnosis and at the time of TE serum levels of 
VCAM-1, ICAM-1 and e-selectin. Levels of adhesion molecules were also measured in age 
and gender matched HC. In IIM patients, median levels (IQR) in ng/mL of VCAM-1 and 
ICAM-1, but not e-selectin were significantly higher than in HC. Median levels (IQR) of 
ICAM-1 and e-selectin were significantly higher in comparators than cases, whereas levels 
of VCAM-1 did not differ between cases and comparators. There was no difference observed 
in the levels of adhesion molecules between the time of IIM diagnosis and the time of TE, 
neither between patients with arterial TE or venous TE. Lower e-selectin levels were 
associated with a higher risk of presenting with TE. The odds of getting TE for lower levels 
of e-selectin were 0.79 times higher than the odds of getting TE for higher e-selectin levels 
(Exp B 0.78, 95% CI 0.62-0.97, p=0.03). Each additional unit of e-selectin decreased the 
chance of developing TE by a factor of 0.24. The association between lower levels of e-
selectin and the risk of TE was maintained even when adjusted for age at diagnosis. Notably, 
low e-selectin levels have been found in individuals with recurrent venous thromboembolism 
in the general population (251, 252). However, high levels of e-selectin have been correlated 
with myocardial infarction and carotid artery atherosclerosis (249, 250). In mouse models, e-
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selectin inhibition decreased venous thrombosis (284). One possible explanation of our 
finding is that, while e-selectin is activated on an endothelium surface, the release of its 
soluble form is decreased (251). One other hypothesis is that, beyond endothelium activation, 
low e-selectin serum levels are related to high turnover due to hypercoagulability (251). 
 
To summarize, this study reported a high prevalence of arterial and venous thrombotic events 
in patients with IIM, especially within the first five years after diagnosis. Screening for risk 
factors should be recommended with particular attention to older male patients with IIM and 
those with essential hypertension. Low serum levels of e-selectin might predict TE in IIM 



















CONCLUSIONS AND FUTURE PERSPECTIVES  
This thesis aimed to add pieces of knowledge in the understanding on the role of the 
autoimmunity against HisRS in the pathogenesis of anti-synthetase syndrome, a distinct 
subgroup of idiopathic inflammatory myopathies.  
In paper I, we demonstrated, for the first time in vivo, that HisRS circulates in healthy 
individuals, strengthening the hypothesis that HisRS exerts physiological functions 
extracellularly other than the canonical intracellular protein synthesis. We also detected 
higher levels of free HisRS in serum of anti-Jo1 negative patients compared to HC, 
suggesting an increased release of the protein in circulation during inflammatory conditions. 
It would be interesting to measure levels of HisRS in serum of patients affected by other 
autoimmune/inflammatory diseases like SLE, RA or sarcoidosis to understand if the 
increased amount of HisRS in serum of anti-Jo1 negative patients is a specific finding in IIM, 
or whether it is generally associated to the inflammatory milieu. In order to investigate which 
cells actively release HisRS, one possibility is to verify if HisRS is bound to microparticles 
and track their origin. In this study we observed that primary human skeletal muscle 
myoblasts release HisRS in the culture medium with increasing levels during differentiation 
in myotubes and upon stimulation with IGF-1. It would be intriguing to verify if the release 
of HisRS from myotubes is affected by other stimuli such as cytokines and if the release 
would change when setting up a muscle culture from muscle biopsies of anti-Jo1 positive and 
negative patients. Investigation of protein network interactions in plasma samples and BAL 
fluid of healthy individuals and IIM/ASS patients would help to identify the molecular 
pathways in which HisRS is involved both physiologically and in pathological conditions, 
expanding previous in vitro studies showing that HisRS takes part in the regulation of 
processes such as immune cell development, angiogenesis, inflammatory response, and 
mTOR signaling (187-189). In addition, our findings promote the hypothesis that 
sequestration of HisRS and, specifically, of the WHEP domain is a major contributor of the 
pathogenesis of ASS. We found that free HisRS is reduced or absent in circulation in presence 
of anti-Jo1 antibodies with inverse correlation between protein and antibody levels. In 
immunized mice with HisRS, presence of anti-HisRS antibodies was associated to 
exacerbation of inflammation in challenged tissues while treatment with HisRS resulted in a 
better control of the inflammatory status. If these observations were replicated, this would 
open the path for a new possible therapeutic intervention in the clinical setting of anti-Jo1+ 
ASS. However, in our study, we could not rule out that immune complexes of anti-Jo1 
antibodies and HisRS have independent pathogenic capacities. Therefore, functional studies 
on anti-Jo1 antibodies are warranted.  
In Paper II, we demonstrated that both total IgG and specifically anti-Jo1 IgG from IIM/ASS 
patients display a pro-inflammatory Fc-glycan profile (i.e. agalactosylation, lower abundance 
of bisected and afucosylated forms) which is overrepresented in patients with ILD. In Paper 
III, we showed that anti-HisRS reactivity levels of IgG and IgA isolated from BALF and 
serum of anti-Jo1+ patients are high already at time of diagnosis and in some cases even 
before diagnosis as well as the affinity levels of antibodies against HisRS-full-length protein. 
High reactivity levels of anti-HisRS-FL antibodies correlated with ILD and poor pulmonary 
function. The findings of both Paper II and III support the hypothesis that the break of 
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tolerance to HisRS might occur prior to the onset of clinical symptoms of IIM/ASS and likely 
in the lungs as possible site of immune activation. One possible model of the pathogenesis of 
anti-Jo1+ ASS could imply the following steps: in genetically predisposed individuals, 
environmental factors such as smoking or recurrent lung infections could induce years or 
months before the occurrence of symptoms an aberrant cleavage by Granzyme B of HisRS 
expressed on epithelial bronchial cells or present in BAL. This would reveal new epitopes of 
HisRS protein, becoming antigenic for the immune system. Then, the antigenic HisRS could 
be presented by lung APC to T cells, inducing the clonal expansion of auto-reactive HisRS-
specific T cells which, in turn, could activate B cells to produce locally in the lungs anti-
HisRS antibodies. Upon HisRS exposure, anti-HisRS antibodies would increase their 
reactivity and affinity and possibly change even the glycan profile, being directly or 
indirectly, trough HisRS sequestration, responsible for lung inflammation and damage. Anti-
HisRS antibodies might then access the systemic bloodstream and reach previously damaged 
muscles (e.g. by trauma) with high amount of regenerating fibers, expressing HisRS during 
differentiation. This would result in muscle inflammation as second target organ after the 
lungs (Figure 12). Similarly, anti-HisRS antibodies might enter the joints causing arthritis. 
To verify this hypothesis, we plan to identify blood samples of anti-Jo1 positive patients 
collected in a Swedish nation-wide biobank years before the diagnosis of IIM/ASS. If the 
presence of anti-Jo1 antibodies before diagnosis is confirmed, it would be interesting to check 
if these pre-clinical anti-Jo1 antibodies already present with a pro-inflammatory Fc-glycan 
profile or if they display pro-inflammatory glycopeptides with the appearance of clinical 
symptoms. In addition, it would be helpful also to study if the glycan profile of anti Jo1 
antibodies correlates with disease activity measures and response to treatment, predicting in 
this case the course of the disease. Finally, if further studies confirmed that the sequestration 
of HisRS and its subsequently abolishment of physiological functions extracellularly are 
crucial events in the pathogenesis of ASS, treatment with HisRS protein to restore normal 
circulating levels in the pre-clinical phase might be used to prevent the development of ASS 
in anti-Jo1 positive patients.   
This thesis also focused on a leading cause of premature death in IIM, the arterial and venous 
thrombosis.  
The results obtained in Paper IV confirmed previous published observations of significantly 
higher incidence of VTE in IIM patients than in the general population, after adjusting for 
education level, comorbidities, cancer, treatment at baseline and competing risk of death. The 
risk of being affected by VTE became extremely elevated during the first year after diagnosis 
of IIM. In patients with IIM, female gender, DM subgroup, older age and diagnosis of cancer 
were found to confer higher risk of presenting with VTE. In Paper V, we showed that one 
out of five IIM patients manifested arterial or venous thrombosis, in particular during the first 
five years after IIM diagnosis and preferentially PE, DVT and MI. Male gender and essential 
hypertension were found to be associated with higher risk of developing TE, while specific 
IIM features and presence of antibodies including anti-phospholipid antibodies did not seem 
to contribute. Moreover, one interesting finding was that lower levels of e-selectin correlated 
with higher odds of getting TE in IIM patients.  
Based on the results of our studies, patients receiving the diagnosis of IIM should be directly 
screened for risk of developing arterial and/or venous thrombosis and accurately monitored 
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especially within the first five years after IIM diagnosis. Extra warning should be reserved to 
old patients with dermatomyositis, essential hypertension and cancer. Impact of prophylactic 
treatment (anti-platelets aggregation drugs and anti-coagulants) should be addressed in 
appropriate randomized trials. In addition, if the finding of the association between low e-
selectin levels and risk of thrombosis was replicated in independent cohorts, e-selectin levels 
might be used as biomarkers to predict the occurrence of thrombosis in IIM patients. Finally, 
the latter observation generates more research questions dealing with the underlying 
biological mechanism behind low e-selectin levels and thrombosis in myositis.  
 
In conclusion, this thesis provides new information supporting the role of autoimmunity 
against HisRS in the pathogenesis of the anti-synthetase syndrome. The discovery of HisRS 
extracellularly, in both healthy individuals and IIM patients, strengthens the hypothesis of 
HisRS exerting other physiological functions beyond the known intracellular protein 
synthesis. The results obtained from the T cell assay and animal models suggest a possible 
immunosuppressive activity of this protein. The inflammatory Fc-glycan profile as well as 
the high reactivity and affinity levels in serum and BALF of anti-Jo1 antibodies (conversely 
undetectable serum HisRS levels) already at the time of and even before diagnosis advocate 
a break of tolerance of the immune system against HisRS already in the pre-clinical phase 
and most likely in the lungs. In fact, high reactive anti-HisRS IgG associate with the presence 
of ILD and, noteworthy, IgG anti-WHEP reactivity in BALF correlate with poor pulmonary 
function.  It appears then to be stringent to verify for the presence of anti-Jo1 antibodies prior 
the onset of the disease and to replicate the results generated by the animal models. This 
could open the path for a new potential preventive and/or therapeutic approach for anti-Jo1 
positive patients with anti-synthetase syndrome.  
This thesis also confirms that patients with idiopathic inflammatory myopathies present with 
a high incidence and prevalence of arterial and venous thrombotic events, especially close to 
diagnosis and in those older, male, with essential hypertension and history of malignancy. 
This should indicate that a proper screening and preventive measures need to be 
recommended in this patient population. Moreover, E-selectin levels could be used as 
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